Page last updated: 2024-11-10

dinoprost

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280363
CHEMBL ID815
CHEBI ID15553
SCHEMBL ID24292
MeSH IDM0023416

Synonyms (139)

Synonym
(+)-prostaglandin f2alpha
b7in85g1hy ,
unii-b7in85g1hy
bdbm50035622
gtpl1884
l-pgf2-alpha
pgf2alpha
dinoprostum
l-prostaglandin f2-alpha
(5z,13e,15s)-9alpha,11alpha,15-trihydroxyprosta-5,13-dien-1-oic acid
CHEBI:15553 ,
dinoprosta
(5z,9alpha,11alpha,13e,15s)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid
D00081
dinoprost (jp17/usan/inn)
prosmon (tn)
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, dl-
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5z,9-alpha,11-alpha,13e,15s)-(+-)-
brn 4153898
prostaglandin f2alpha, dl-
dl-prostaglandin f2-alpha
(+-)-pgf2-alpha
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, (+-)-
dinoprostum [inn-latin]
prostaglandin f2 alpha
brn 2225571
pgf2 alpha
pgf2
prostaglandin f(sub 2a)
prostaglandin f2-alpha
9,11,15-trihydroxyprosta-5,13-dien-1-oic acid
hsdb 3315
(e,z)-(1r,2r,3r,5s)-7-(3,5-dihydroxy-2-((3s)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid
9alpha,11alpha-pgf2
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, (1r-(1alpha(z),2beta(s*,e),3alpha,5alpha))-
dinoprost [usan:inn:ban:jan]
prostin f2-alpha
7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid
pgf-2alpha
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, l-
pgf2-alpha
ccris 4253
(5z,9alpha,11alpha,13e,15s)-9,11,15-trihydroxyprosta-3,13-dien-1-oic acid
dinoprosta [inn-spanish]
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5z,9alpha,11alpha,13e,15s)-
9s,11r,15s-trihydroxy-5z,13e-prostadienoic acid
LMFA03010002
BSPBIO_001494
PDSP2_000079
amoglandin
9a,11a-pgf2
C00639
prostin f 2 alpha
u 14583
(5z,13e)-(15s)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate
7-[3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid
551-11-1
prostaglandin f2alpha
prostin f2alpha
protamodin
dinoprost
prostaglandin f2a
(5z,9alpha,11alpha,13e,15s)-9,11,15-trihydroxyprosta-5,13-dienoate
prostaglandin f2.alpha.
u-14583
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
prosta-10,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5z,9.alpha.,11.alpha.,13e,15s)
NCGC00160385-01
NCGC00160385-02
IDI1_033964
NCGC00160385-04
9alpha,11beta pgf2
f2alpha, prostaglandin
alpha, pgf2
f2 alpha, prostaglandin
HMS2089F11
HMS1989K16
u-14,583
CHEMBL815 ,
prosmon
BML1-F08
HMS1361K16
HMS1791K16
NCGC00160385-06
NCGC00160385-05
dtxsid9022946 ,
cas-551-11-1
dtxcid602946
tox21_111777
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-((s)-(e)-3-hydroxyoct-1-enyl)-cyclopentyl]hept-5-enoic acid
A830494
P1885
(+-)-pgf2alpha
prostaglandin f2-alpha, racemic mixt.
pgf2-alpha racemic mixt.
23518-25-4
dinoprost [who-dd]
dinoprost [hsdb]
dinoprost [usan]
dinoprost [inn]
dinoprost [mart.]
dinoprost [jan]
prostaglandin f2.alpha. [mi]
CCG-208257
SCHEMBL24292
CS-4232
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-{(e)-(3s)-3-hydroxy-1-octenyl}-cyclopentyl]-5-heptenoic acid
PXGPLTODNUVGFL-YNNPMVKQSA-N
(z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((s,e)-3-hydroxyoct-1-en-1-yl)cyclopentyl)hept-5-enoic acid
HY-12956
HMS3648N11
HMS3402K16
AKOS030526160
SR-01000721847-4
SR-01000721847-2
sr-01000721847
(5z,9alpha,11alpha,13e,15s)-9,11,15-trihydroxyprosta-5,13-dienoic acid
pgf2alpha-[d4]
DB12789
Q421375
mfcd00135231
13535-33-6
sr-01000946457
SR-01000946457-1
AMY30098
15(r)-prostaglandin f2 alpha
15-epi pgf2alpha
AS-56892
(5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoic acid
(z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((s,e)-3-hydroxyoct-1-enyl)-cyclopentyl)-hept-5-enoic acid
EX-A4115A
EN300-21689745
prostaglandin-f2alpha
7-(3, 5-dihydroxy-2-(3-hydroxyl-1-octenyl) cyclopentyl)-5-heptenoic acid
g02ad01
dinoprostum (inn-latin)
dinoprost (mart.)
dinoprosta (inn-spanish)
(5z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((1e,3s)-3-hydroxyoct-1-en-1-yl)cyclopentyl)hept-5-enoic acid

Research Excerpts

Effects

ExcerptReferenceRelevance
"Dinoprost tromethamine has a short half-life of approximately 7 to 8min."( Effects of cloprostenol sodium at final prostaglandin F2α of Ovsynch on complete luteolysis and pregnancy per artificial insemination in lactating dairy cows.
Martins, JP; Neuder, LM; Policelli, RK; Pursley, JR; Raphael, W, 2011
)
1.09
"Dinoprost tromethamine has a short half-life of approximately 7 to 8min."( Effects of cloprostenol sodium at final prostaglandin F2α of Ovsynch on complete luteolysis and pregnancy per artificial insemination in lactating dairy cows.
Martins, JP; Neuder, LM; Policelli, RK; Pursley, JR; Raphael, W, 2011
)
1.09

Treatment

ExcerptReferenceRelevance
"Both dinoprost treated groups had a mean calving interval of 366 days compared with 378 for controls."( Evaluation of single and double artificial insemination regimes as methods of shortening calving intervals in dairy cows treated with dinoprost.
Henderson, DC; Young, IM, 1981
)
0.92

Toxicity

ExcerptReferenceRelevance
" the LD50 for cis-H-bu-MDI was 75 mg/kg (single intramuscular dose)."( Evaluation of the antiabortifacient and embryotoxic effects of methylenedioxyindene and methylenedioxyindan calcium antagonists.
Olah, ME; Rahwan, RG, 1986
)
0.27
" The results indicated that more toxic effects could be observed both in rats and human hepatoma cell line treated with TCHQ than its parent compound, PCP."( Oxidative stress and liver toxicity in rats and human hepatoma cell line induced by pentachlorophenol and its major metabolite tetrachlorohydroquinone.
Chang, WC; Ho, YS; Lee, CC; Liou, HB; Wang, YJ, 2001
)
0.31
" Adverse gastrointestinal events were recorded more often in the Hemabate group."( A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage.
Gordon, H; Lamont, RF; Logue, M; Morgan, DJ, 2001
)
0.31
" The side effect profile of unoprostone appears to be comparable to other established IOP-lowering agents."( A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Kapik, B; Mertz, B; Nordmann, JP; Schwenninger, C; Shams, N; Yannoulis, NC, 2002
)
0.31
"Our objectives were to determine whether repeated administration of prostaglandin F2alpha (PGF2alpha) to simulate the endogenous mode of secretion would be more effective than a single injection in inducing luteolysis and enable use of smaller doses less likely to cause adverse side effects."( Effectiveness of a two-dose regimen of prostaglandin administration in inducing luteolysis without adverse side effects in mares.
Alexander, SL; Irvine, CH; McKeough, VL; Taylor, TB; Turner, JE, 2002
)
0.31
" With unoprostone monotherapy, most adverse events were mild or moderate and transient in nature."( Safety of unoprostone isopropyl as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.
de Arruda Mello, PA; Haque, RM; Yannoulis, NC, 2002
)
0.31
"15% was safe for use in patients with mild to moderate asthma, without affecting the response to bronchodilator therapy."( Safety of unoprostone isopropyl 0.15% ophthalmic solution in patients with mild to moderate asthma.
Crame, N; Gunawardena, KA; Mertz, B; Shams, N,
)
0.13
" 1,4-Benzoquinone (BQ), a toxic chemical implicated in benzene toxicity, was used as a reference compound."( Cytotoxicity of a Quinone-containing Cockroach Sex Pheromone in Human Lung Adenocarcinoma Cells.
Carr, BA; Chang, FN; Krolikowski, P; Ma, B, 2007
)
0.34
" Our study demonstrated that a combination of aspirin and gammaT, but not a combination of aspirin and alphaT, has some advantage over aspirin alone in terms of anti-inflammatory effects and attenuation of aspirin-induced adverse effects."( A combination of aspirin and gamma-tocopherol is superior to that of aspirin and alpha-tocopherol in anti-inflammatory action and attenuation of aspirin-induced adverse effects.
Ames, BN; Jiang, Q; Moreland, M; Yin, X, 2009
)
0.35
" Resin monomers are the main toxic components in DBA, and the ester group is crucial for monomer toxicity."( Carboxylesterase expression in human dental pulp cells: role in regulation of BisGMA-induced prostanoid production and cytotoxicity.
Chan, CP; Chang, MC; Chuang, FH; Jeng, JH; Jeng, PY; Lee, JJ; Lin, HJ; Lin, LD; Tseng, WY; Wang, TM, 2012
)
0.38
" Safety assessments included vital signs, comprehensive ophthalmic exams, and treatment-emergent adverse events (AEs)."( Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
Araie, M; Kawase, K; Vittitow, JL; Weinreb, RN, 2016
)
0.43
"024% was safe and well-tolerated in Japanese subjects with OAG or OHT when used for up to 1 year."( Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
Araie, M; Kawase, K; Vittitow, JL; Weinreb, RN, 2016
)
0.43
" Some ophthalmic formulations with β-receptor blocking or α-receptor stimulating actions are reported to cause systemic adverse events such as a decrease in heart rate and blood pressure."( Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
Inoue, M; Kawakami, H; Ohyama, K, 2017
)
0.46
" We hypothesized that administrating of N-acetylcysteine (NAC) prevents serious adverse events including cardiac complications in TDT patients by reducing systemic oxidative stress and balancing cardiac sympathovagal control."( N-acetylcysteine Restored Heart Rate Variability and Prevented Serious Adverse Events in Transfusion-dependent Thalassemia Patients: a Double-blind Single Center Randomized Controlled Trial.
Chattipakorn, N; Chattipakorn, SC; Pattanakuhar, S; Phrommintikul, A; Srichairattanakool, S; Tantiworawit, A, 2020
)
0.56
"Carfilzomib's (Cfz) adverse events in myeloma patients include cardiovascular toxicity."( Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Andreadou, I; Dimopoulos, MA; Doerschmann, H; Efentakis, P; Kastritis, E; Nikolaou, PE; Siemer, S; Stauber, R; Terpos, E; Wenzel, P; Witzler, C, 2020
)
0.56
" Jennies were monitored for 30 minutes following treatment, and adverse effects were recorded."( Efficacy and Side Effects of Low Single Doses of Cloprostenol Sodium or Dinoprost Tromethamine to Induce Luteolysis in Donkeys.
French, H; Gilbert, R; Kent, A; Landers, M; Peterson, E; Segabinazzi, LGTM, 2021
)
0.85

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic variables were calculated using statistical moment methods."( Pharmacokinetics of flunixin and its effect on prostaglandin F2 alpha metabolite concentrations after oral and intravenous administration in heifers.
Odensvik, K, 1995
)
0.29
" Additionally, the steady-state pharmacokinetic parameters were determined after the subjects were administered one capsule three times daily for 28 consecutive days."( An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.
Bernstein, HJ; Brinda, BJ; Chavin, KD; Markowitz, JS; Patrick, KS; Zhu, HJ, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
"Abortion was attempted in 316 healthy women in early pregnancy within 7 weeks with the RU486 alone (600mg in a single oral dose) or in combination with a PG (15-dl-methyl-PGF2 alpha-methyl-ester) 1 mg suppository."( [Termination of early pregnancy using RU 486 alone or in combination with prostaglandin. The RU 486 Collaboration Group].
, 1990
)
0.28
"The simultaneous determination of prostaglandin E2 (PGE2), prostaglandin F2 alpha (PGF2 alpha) and 6-oxoprostaglandin F1 alpha (6-oxo-PGF1 alpha) in urine using immunoaffinity chromatography in combination with negative ion chemical ionization gas chromatography-tandem mass spectrometry (NICI-GC-MS-MS) is described."( Simultaneous determination of the primary prostanoids prostaglandin E2, prostaglandin F2 alpha and 6-oxoprostaglandin F1 alpha by immunoaffinity chromatography in combination with negative ion chemical ionization gas chromatography-tandem mass spectrometr
Mackert, G; Reinke, M; Schweer, H; Seyberth, HW, 1989
)
0.28
"Induction of 2nd trimester abortion was studied by administration of the acridine derivative Rivanol in combination with an intravenous (iv) drip infusion of oxytocin or prostaglandin (PGF2alpha), alone or in combination."( Second-trimester abortion by extra-amniotic instillation of Rivanol combined with intravenous administration of oxytocin or prostaglandin F2 alpha.
Hamberger, L; Klinte, I; Wiqvist, N, 1983
)
0.27
"We have previously shown that medroxyprogesterone acetate (MPA), either alone or combined with conjugated equine estrogens (CEE), significantly decreased insulin sensitivity (SI), compared with both untreated controls and those treated with CEE alone."( Insulin sensitivity and cardiovascular risk factors in ovariectomized monkeys with estradiol alone or combined with nomegestrol acetate.
Cefalu, WT; Greaves, KA; Thomas, MJ; Wagner, JD; Williams, JK; Zhang, L, 1998
)
0.3
"To observe the effect of 15-methyl PGF2 alpha methyl ester (PG05) in combination with tyrosine hydrazide (TH) on early pregnancy in mice."( [Effect of 15-methyl PGF2 alpha methyl ester combined with tyrosine hydrazide on early pregnancy in mice].
Duan, H; Wang, N; Zheng, W, 1999
)
0.3
" Serum progesterone level of mice treated with PG05 combined with TH was found to be markedly lower than that of animals given PG05 or TH alone."( [Effect of 15-methyl PGF2 alpha methyl ester combined with tyrosine hydrazide on early pregnancy in mice].
Duan, H; Wang, N; Zheng, W, 1999
)
0.3
"Nonlactating Bos indicus x Bos taurus cows were used in three herds to determine the efficacy of different PGF2alpha treatments in combination with GnRH and melengestrol acetate (MGA) for a timed artificial insemination protocol."( Synchronization of Bos indicus x Bos taurus cows for timed artificial insemination using gonadotropin-releasing hormone plus prostaglandin F2alpha in combination with melengestrol acetate.
Barthle, CR; Bridges, GA; Dahms, MK; Hiers, EA; Portillo, GE; Rae, DO; Thatcher, WW; Yelich, JV, 2003
)
0.32
"To determine the effect of exogenous 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] combined with induced parturition on calcium (Ca) metabolism, cows received a single intramuscular injection of 1,25(OH)2D3 and prostaglandin F(2alpha) (PGF(2alpha)) closely before calving."( Calcium metabolism in cows receiving an intramuscular injection of 1,25-dihydroxyvitamin D3 combined with prostaglandin F(2alpha) closely before parturition.
Ayukawa, Y; Lee, I; Naito, Y; Oboshi, K; Yamagishi, N, 2005
)
0.33
"The objective of this study was to investigate cystic ovarian disease (COD) in commercial Japanese Black cows and to evaluate the efficacy of 7-day insertion of an intravaginal progesterone insert (CIDR) combined with prostaglandin F(2alpha) (PGF(2alpha)) at CIDR removal."( Efficacy of intravaginal progesterone administration combined with prostaglandin f(2alpha) for cystic ovarian disease in Japanese Black cows.
Haneishi, T; Iwakuma, A; Kajisa, M; Kamimura, S; Suzuki, Y, 2008
)
0.35
"This study evaluated fertility in swamp buffalo after synchronization of ovulation combined with fixed time artificial insemination."( Fertility of swamp buffalo following the synchronization of ovulation by the sequential administration of GnRH and PGF₂alpha combined with fixed-timed artificial insemination.
Chaikhun, T; De Rensis, F; Rattanatep, J; Techakumphu, M; Tharasanit, T, 2010
)
0.36
") administration of ceftiofur was used for five days in combination with flunixin for three days."( Treatment of dairy cows with PGF2α or NSAID, in combination with antibiotics, in cases of postpartum uterine inflammation.
Jeremejeva, J; Kask, K; Orro, T; Waldmann, A, 2012
)
0.38
"To observe the clinical efficacy of acupuncture combined with auricular point sticking for menstrual headache and to discuss its mechanism."( [Efficacy of acupuncture combined with auricular point sticking on the content of serum prostaglandin F2α, and plasma arginine vasopressin in patients with menstrual headache].
Gao, F; Li, W; Li, X; Liang, Y; Liu, L; Ma, H; Sun, L; Xu, X, 2015
)
0.42
" The observation group was treated with body acupuncture combined with auricular point sticking and the control group was treated with flunarizine hydrochloride capsules orally."( [Efficacy of acupuncture combined with auricular point sticking on the content of serum prostaglandin F2α, and plasma arginine vasopressin in patients with menstrual headache].
Gao, F; Li, W; Li, X; Liang, Y; Liu, L; Ma, H; Sun, L; Xu, X, 2015
)
0.42
"Body acupuncture combined with auricular point sticking achieves positive efficacy for menstrual headache and its mechanism could be related to regulating the abnormal levels of serum PGF2α and plasma AVP."( [Efficacy of acupuncture combined with auricular point sticking on the content of serum prostaglandin F2α, and plasma arginine vasopressin in patients with menstrual headache].
Gao, F; Li, W; Li, X; Liang, Y; Liu, L; Ma, H; Sun, L; Xu, X, 2015
)
0.42
" Astaxanthinin, combined with vitamin E, vitamin C, and calorie restriction, was able to ameliorate, in part, infertility in male rats."( Effect of Astaxanthin, Vitamin E, and Vitamin C in Combination with Calorie Restriction on Sperm Quality and Quantity in Male Rats.
Rahbar, AR; Shakoori Mahmoodabadi, MM; Vahidinia, A, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" When PGF2 alpha was infused at a rate of 5 mumols kg-1 h-1, the absorption rate of water decreased from 51."( The effect of dinoprost on transport of water and imipramine through rat small intestinal membranes.
Arimori, K; Deshimaru, M; Nakano, M, 1992
)
0.64
" This study suggests that the endothelium plays a necessary role in PGF2 alpha potentiation of vasoconstrictor response, possibly through the release of an endothelial vasoconstrictor factor which probably increases the Ca2+ bioavailability for the contraction."( Endothelium and Ca2+ in the prostaglandin F2 alpha potentiation of vasoconstrictor responses.
Aristegui, PM; Enero, MA, 1990
)
0.28
" The absorption rate was first order."( Physical model approach to gastrointestinal absorption of prostaglandins II: In situ rat intestinal absorption of dinoprost.
Ho, NF; Morozowich, W; Park, JY, 1984
)
0.48
" Decreased concentrations in non-resuscitated patients may have been a result of exhaustion of the neuroendocrine and eicosanoid systems, or may be due to differences in bioavailability at the site of blood sampling based upon differences in hemodynamics."( Concentrations of prolactin and prostaglandins during and after cardiopulmonary resuscitation.
Bothner, U; Georgieff, M; Keller, A; Lindner, IM; Lindner, KH; Strohmenger, HU, 1995
)
0.29
" We conclude that an increase in prostaglandin bioavailability precedes the onset of spontaneous human parturition."( Increase in prostaglandin bioavailability precedes the onset of human parturition.
Garrido, J; Ghezzi, F; Gomez, R; Hasbun, J; Mazor, M; Mitchell, MD; Munoz, H; Parra, M; Polanco, M; Romero, R; Tolosa, JE; Valverde, V, 1996
)
0.29
" The favorable separation index for these compounds appeared to be due to their metabolic stability at the corneal surface and conjunctiva combined with sufficient bioavailability for ocular hypotension."( Ocular penetration and bioconversion of prostaglandin F2alpha prodrugs in rabbit cornea and conjunctiva.
Chien, DS; Tang-Liu, DD; Woodward, DF, 1997
)
0.3
"1% when administered intravenously at 30 microg/kg to the chronically hypoxic rats and had an apparent oral bioavailability of about 19."( 4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
Adachi, H; Ishibashi, K; Ishihara, H; Kabasawa, Y; Kakiki, M; Kodama, K; Matsukura, M; Miyazaki, K; Nishino, M; Ozaki, H; Takase, Y; Watanabe, N, 2000
)
0.31
" Collectively, the data show a decreased NO bioavailability in OP animals that is due in part to the increased oxidative stress."( Oxidative stress in a rat model of obesity-induced hypertension.
Davies, MJ; Dobrian, AD; Lauterio, TJ; Prewitt, RL; Schriver, SD, 2001
)
0.31
" bioavailability may represent a common factor responsible for the vascular and glomerular dysfunction."( Oxidative stress and renal dysfunction in salt-sensitive hypertension.
Loscalzo, J; Rudd, MA; Trolliet, MR, 2001
)
0.31
"The present study evaluated whether reactive oxygen species-induced alterations in bioavailability of 20-HETE in the kidney contribute to the antihypertensive and renoprotective actions of antioxidant therapy with Tempol in the Dahl salt-sensitive (DS) rat."( Contributions of 20-HETE to the antihypertensive effects of Tempol in Dahl salt-sensitive rats.
Hoagland, KM; Maier, KG; Roman, RJ, 2003
)
0.32
" We hypothesize that PGF2alpha initiates luteolysis in vivo, at least in part, by increasing the bioactivity or bioavailability of cytokines, such as FasL and that multiple endocrine factors work in concert to activate caspase-3-driven apoptosis during luteolysis."( Prostaglandin F2alpha- and FAS-activating antibody-induced regression of the corpus luteum involves caspase-8 and is defective in caspase-3 deficient mice.
Carambula, SF; Flavell, RA; Gonçalves, PB; Lynch, MP; Matikainen, T; Pru, JK; Rueda, BR; Tilly, JL, 2003
)
0.32
"We examined the bioavailability of vitamin C in orange juice processed using high pressure (HP) and its effects on plasma levels of vitamin C, uric acid (UA), F2-isoprostanes (8-epiPGF(2alpha)), C-reactive protein (CRP) and prostaglandin E(2) (PGE(2)) in a healthy human population."( High-pressurized orange juice consumption affects plasma vitamin C, antioxidative status and inflammatory markers in healthy humans.
Cano, MP; de Ancos, B; Granado, F; Martín, A; Olmedilla, B; Plaza, L; Sánchez-Moreno, C, 2003
)
0.32
"The objectives were to assess the bioavailability of vitamin C from orange juice and its influence on plasma vitamin C and 8-epi-prostaglandin F(2 alpha) (8-epi-PGF(2 alpha)) concentrations in a healthy human population."( Effect of orange juice intake on vitamin C concentrations and biomarkers of antioxidant status in humans.
Cano, MP; de Ancos, B; Granado, F; Martín, A; Olmedilla, B; Plaza, L; Sánchez-Moreno, C, 2003
)
0.32
" The present results suggest that the protective effects of lansoprazole can be ascribed to a reduction of gastric oxidative injury, resulting in an increased bioavailability of mucosal sulfhydryl compounds."( Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds.
Blandizzi, C; Colucci, R; Del Tacca, M; Fornai, M; Lazzeri, G; Lubrano, V; Natale, G; Vassalle, C, 2004
)
0.32
" Therefore, the objectives of this study were to assess the bioavailability of vitamin C from pulsed electric fields-treated orange juice in comparison with freshly squeezed orange juice and its impact on 8-epiPGF(2alpha) concentrations (biomarker of lipid peroxidation) in a healthy human population."( Pulsed electric fields-processed orange juice consumption increases plasma vitamin C and decreases F2-isoprostanes in healthy humans.
Cano, MP; de Ancos, B; Elez-Martínez, P; Granado, F; Martín, A; Martín-Belloso, O; Olmedilla, B; Plaza, L; Sánchez-Moreno, C, 2004
)
0.32
" The second aim was to evaluate whether scavenging of O2- by infusion of the superoxide dismutase mimetic tempol increases NO bioavailability which therefore should augment BP and renal functional responses to L-NAME."( Roles of nitric oxide and oxidative stress in the regulation of blood pressure and renal function in prehypertensive Ren-2 transgenic rats.
Bader, M; Cervenka, L; Ganten, D; Kazdová, L; Kramer, HJ; Novotná, J; Opocenský, M; Vanecková, I, 2005
)
0.33
"The bioavailability of vitamin C from pulsed electric fields (PEF)-treated vegetable soup in comparison with freshly made (FM) vegetable soup-gazpacho-and its impact on 8-epiPGF(2alpha) and uric acid concentrations in a human population were assessed."( Intake of Mediterranean vegetable soup treated by pulsed electric fields affects plasma vitamin C and antioxidant biomarkers in humans.
De Ancos, B; Elez-Martínez, P; Granado, F; Martín, A; Martín-Belloso, O; Olmedilla, B; Pilar Cano, M; Plaza, L; Sánchez-Moreno, C, 2005
)
0.33
" In this work, the bioavailability of vitamin C from a Mediterranean vegetable soup (gazpacho) constituted mainly of tomato, pepper and cucumber, and its influence on plasma vitamin C, 8-epi-prostaglandin F(2alpha) (8-epi-PGF2alpha), prostaglandin E2 (PGE2), monocyte chemotactic protein-1 (MCP-1), and the cytokines/tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6 concentrations in a healthy human population were assessed."( Mediterranean vegetable soup consumption increases plasma vitamin C and decreases F2-isoprostanes, prostaglandin E2 and monocyte chemotactic protein-1 in healthy humans.
Cano, MP; de Ancos, B; Granado, F; Martín, A; Olmedilla, B; Plaza, L; Sánchez-Moreno, C, 2006
)
0.33
" This suggests a strikingly rapid bioavailability of bioeffective compounds after oral intake of the extract."( Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol).
Chovanová, Z; Duracková, Z; Högger, P; Liptáková, A; Muchová, J; Schäfer, A; Sumegová, K, 2006
)
0.33
" The protective effects may be attributable to restoration of NO bioavailability in the circulation."( Antioxidant N-acetylcysteine restores systemic nitric oxide availability and corrects depressions in arterial blood pressure and heart rate in diabetic rats.
Guo, Z; McNeill, JH; Nagareddy, PR; Xia, Z; Zhang, W, 2006
)
0.33
" We previously demonstrated that CyA results in impairment of nitric oxide bioavailability and enhanced sensitivity to endothelin-1 (ET-1)."( Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine.
Delgado, D; Miriuka, S; Ramzy, D; Rao, V; Ross, HJ; Tumiati, LC; Xu, N, 2006
)
0.33
"Superoxide anions react with nitric oxide to form peroxynitrite and hence reduce the bioavailability of nitric oxide in the arteries."( Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension.
Floyd, M; Guo, Z; Nyanda, AM; Potts, J; Ross, J; Sharan, C; Xiang, W; Yang, H; Zhou, L, 2006
)
0.33
" Secondary outcome measures were changes in plasma markers of vasodilative nitric oxide (S-nitrosoglutathione) and oxidative stress (8-isoprostane), and bioavailability of cocoa polyphenols."( Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial.
Jung, N; Lehmann, C; Roesen, R; Schömig, E; Taubert, D, 2007
)
0.34
" The missing systemic bioavailability of PETN and PEtriN may explain the discrepancy between in vitro and in vivo findings."( Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate.
Daiber, A; Glusa, E; Koenig, A; Konter, J; Lange, K; Lehmann, J; Stalleicken, D, 2007
)
0.34
"These findings suggest that acute moderate-intensity exercise induces vasodilation through an increase in NO bioavailability in humans and that high-intensity exercise increases oxidative stress."( Acute moderate-intensity exercise induces vasodilation through an increase in nitric oxide bioavailiability in humans.
Chayama, K; Goto, C; Higashi, Y; Jitsuiki, D; Kawamura, M; Nishioka, K; Sakagutchi, A; Umemura, T; Yoshizumi, M, 2007
)
0.34
"Impaired nitric oxide (NO) bioavailability and low levels of circulating endothelial progenitor cells (EPC) are correlated to an increased risk for development of cardiovascular diseases."( Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I.
Bauersachs, J; Fleissner, F; Jakob, M; Klink, I; Stichtenoth, DO; Thum, T; Tsikas, D, 2007
)
0.34
" Before and after GH treatment, we analyzed markers of NO bioavailability and EPC levels."( Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I.
Bauersachs, J; Fleissner, F; Jakob, M; Klink, I; Stichtenoth, DO; Thum, T; Tsikas, D, 2007
)
0.34
"GH treatment induced markers of increased NO bioavailability and enhanced circulating EPC numbers in healthy volunteers."( Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I.
Bauersachs, J; Fleissner, F; Jakob, M; Klink, I; Stichtenoth, DO; Thum, T; Tsikas, D, 2007
)
0.34
" We report for the first time that CYP 2C inhibition reduces oxidative stress (measured as plasma levels of 8-isoprostane), increases NO bioavailability (measured as NO(2)(-)) and restores endothelial function in db/db mice without affecting plasma glucose levels."( Sulfaphenazole treatment restores endothelium-dependent vasodilation in diabetic mice.
Elmi, S; Granville, DJ; Hunter, AL; Khazaei, M; Laher, I; Moien-Afshari, F; Rahman, MM; Sallam, NA; Teng, X, 2008
)
0.35
"D/L-Nebivolol is a lypophilic beta1-adrenergic antagonist which is devoid of intrinsic sympathomimetic activity and can increase nitric oxide (NO) bioavailability with its subsequent vasodilating properties."( Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction.
Arévalo, M; Cenador, B; Colaço, A; Esteller, A; Evangelista, S; López-Novoa, JM; Pires, MJ; Rodríguez-Peña, AB; Sánchez-Rodríguez, A, 2007
)
0.34
" One possible mechanism for this effect is reduced bioavailability of nitric oxide, a key mediator of angiogenesis, secondary to increased oxygen free radicals."( Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia.
Bianchi, C; Boodhwani, M; Clements, RT; Feng, J; Mieno, S; Ramlawi, B; Sellke, FW; Sodha, NR; Xu, SH,
)
0.13
" We conclude that the vascular benefits of moderate levels of exercise were independent of changes in myogenic tone or hyperglycemic status and primarily involved increased nitric oxide bioavailability in the coronary microcirculation."( Exercise restores coronary vascular function independent of myogenic tone or hyperglycemic status in db/db mice.
Elmi, S; Ghosh, S; Khazaei, M; Laher, I; Moien-Afshari, F; Rahman, MM; Sallam, N, 2008
)
0.35
" The aim of the present study was to investigate a potential link between NO synthesis and bioavailability and oxidative stress in the circulation of subjects performing high-intensive endurance exercise."( Positive correlation between plasma nitrite and performance during high-intensive exercise but not oxidative stress in healthy men.
Dreissigacker, U; Maassen, N; Tsikas, D; Wendt, M; Wittke, T, 2010
)
0.36
" In this study, we investigated the effects of iloprost infusion on urinary 11-dehydro-TXB₂ and 8-iso-PGF(₂α) excretion rate, as in vivo indexes of thromboxane-dependent platelet activation and lipid peroxidation, respectively, and on platelet-derived proinflammatory sCD40L and nitric oxide bioavailability in 44 patients with CLI while on chronic treatment with low-dose aspirin."( Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost.
Cuccurullo, C; Davì, G; Di Iorio, P; Di Michele, D; Di Ruscio, P; Ferrante, E; Lattanzio, S; Laurora, G; Lessiani, G; Liani, R; Sgrò, G; Simeone, E; Vazzana, N, 2011
)
0.37
" We evaluated the antihypertensive effects of sodium nitrite given in drinking water for 4 weeks in two-kidney one-clip (2K1C) hypertensive rats and the effects induced by nitrite on NO bioavailability and oxidative stress."( Sodium nitrite downregulates vascular NADPH oxidase and exerts antihypertensive effects in hypertension.
Amaral, JH; Ferreira, GC; Marçal, DM; Montenegro, MF; Pereira, RP; Pinheiro, LC; Reis, RI; Sakamoto, EK; Tanus-Santos, JE, 2011
)
0.37
"In experimental models of polycystic kidney disease impaired bioavailability of nitric oxide (NO) and elevated mRNA expression of oxidative stress markers at the kidney level was noted."( Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease.
Georgianos, PI; Grekas, DM; Kapoulas, S; Makedou, A; Makedou, K; Raptis, V; Sarafidis, PA; Sioulis, A, 2013
)
0.39
" Reactive oxygen species reduce nitric oxide bioavailability and have a pivotal role in endothelial function."( Plasma 8-isoprostane levels are associated with endothelial dysfunction in resistant hypertension.
Barbaro, NR; de Faria, AP; Ferreira-Melo, SE; Fontana, V; Modolo, R; Moreno, H; Pansani, IF; Sabbatini, AR, 2014
)
0.4
"046), and nitric oxide bioavailability (P = ."( Acute Impact of Tobacco vs Electronic Cigarette Smoking on Oxidative Stress and Vascular Function.
Biondi-Zoccai, G; Carnevale, R; Chimenti, I; De Falco, E; Frati, G; Loffredo, L; Marullo, AG; Nocella, C; Perri, L; Peruzzi, M; Sciarretta, S; Valenti, V; Violi, F, 2016
)
0.43
" Retrospectively, we studied 37 subjects who had participated in a dietary intervention focused on vitamin D bioavailability from white button mushrooms (WBM)."( A Retrospective Study in Adults with Metabolic Syndrome: Diabetic Risk Factor Response to Daily Consumption of Agaricus bisporus (White Button Mushrooms).
Beelman, RB; Cai, W; Calvo, MS; Goh, BC; Kalaras, MD; Mehrotra, A; Nadkarni, G; Uribarri, J; Wang, L, 2016
)
0.43
"In a cross-sectional study we analysed endothelial function, as assessed by flow-mediated dilation (FMD), and oxidative stress, as assessed by Nox2 activation, serum isoprostanes and nitric oxide bioavailability (NOx), in patients with NASH (n = 19), FLD (n = 19) and controls (n = 19)."( Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis.
Angelico, F; Baratta, F; Battaglia, S; Carnevale, R; Ceci, F; Del Ben, M; Loffredo, L; Ludovica, P; Nocella, C; Novo, M; Pannitteri, G; Violi, F, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In spite of the reduced dosage of each component, the instillation abortion interval still remained 17."( Use of prostaglandin, hypertonic saline and oxytocin for second-trimester abortion.
Kerenyi, T; Muzsnai, D, 1979
)
0.26
" Of the 4 dosage schedules, Group 3 exhibited the most satisfactory results, with 15."( Use of prostaglandin, hypertonic saline and oxytocin for second-trimester abortion.
Kerenyi, T; Muzsnai, D, 1979
)
0.26
" Increasing dosages of the vasoconstrictors below their threshold of systemic activity were employed in order to obtain dose-response curves of the hand veins congested at a venous occlusion pressure of 40 mmHg."( Oral administration of carvedilol and prazosin inhibits the prostaglandin F2 alpha- and noradrenaline-induced contraction of human hand veins in vivo.
Beermann, C; Belz, GG; Schloos, J, 1992
)
0.28
" Dose-response curves showed that the rank order of potency for stimulation of production of inositol phosphates was AVP > ET-1 > PGF2 alpha, similar to the sensitivity of blood vessels to these agents."( Inositol phosphate production in response to [Arg8]vasopressin, endothelin 1, and prostaglandin F2 alpha in rat aorta and mesenteric arteries.
Nguyen, PV; Parent, A; Schiffrin, EL; Yang, XP, 1992
)
0.28
" Moreover, these agonists caused a shift of the dose-response curve for phenylephrine to the right in a parallel fashion in non-preconstricted preparations."( Vascular alpha-1 antagonistic and agonistic effects of beta adrenoceptor agonists in rabbit common carotid arteries.
Chiba, S; Fujiwara, T, 1992
)
0.28
" In the DA1 blockade groups the ANP dose-response curve was shifted to the right, in a parallel fashion."( Interaction of atrial natriuretic peptide with DA1 receptors in preconstricted isolated perfused rat lungs.
Polak, MJ; Romano, JT; Taylor, DA, 1992
)
0.28
" Oral administration of 50 mg carvedilol led to a rightward shift in the dose-response curves of angiotensin II, norepinephrine, and PGF2 alpha."( Constriction of human dorsal hand veins in vivo with several vasoconstrictors and the influence of oral administration of carvedilol.
Beermann, C; Belz, GG; Schloos, J, 1992
)
0.28
" Compound MV 8612 (8 and 16 microM) and MV 8610 (12 and 24 microM) caused a graded rightward displacement of BK dose-response curves in the isolated guinea pig trachea (dose ratio 2- to 4-fold)."( Effect of compounds from Mandevilla velutina on bradykinin-mediated contractile and relaxant responses of the isolated guinea pig trachea.
Calixto, JB; Cruz, AB; Medeiros, YS; Yunes, RA, 1992
)
0.28
"12% reduced IOP in a dose-dependent manner with neither systemic nor local ocular controversial side effects at those dosage levels."( [Ocular effects of topical instillation of UF-021 ophthalmic solution in healthy volunteers].
Koyano, S; Murao, M; Okita, M; Takase, M; Ueno, R, 1992
)
0.28
" The highest antibiotic dosage induced an abrupt decline of PGI2 synthesis, down to 26%, in animals with the longest duration of treatment."( Prostaglandin synthesis by the lateral cochlear wall under streptomycin influence.
Aharinejad, S; Firbas, W; Franz, P; Sinzinger, H, 1992
)
0.28
" In a dose-response trial, the magnitude of the [Ca2+]i response did not vary, although a decreasing number of cells responded to decreasing PGF2 alpha concentrations (10(-5) to 10(-9) M)."( Cytosolic free calcium increased by prostaglandin F2 alpha (PGF2 alpha), gonadotropin-releasing hormone, and angiotensin II in rat granulosa cells and PGF2 alpha in human granulosa cells.
Baimbridge, KG; Currie, WD; Leung, PC; Li, W; Yuen, BH, 1992
)
0.28
" In 15 unilaterally PGF2 alpha-treated rabbits, after 4-6 hr dosing Fu was 49 +/- 14% higher in the treated than in the contralateral control eyes."( The effect of topical PGF2 alpha on uveoscleral outflow and outflow facility in the rabbit eye.
Gabelt, B; Kaufman, PL; Poyer, JF, 1992
)
0.28
" Dose-response relationships for an endothelial-dependent vasodilator, acetylcholine, and an endothelial-independent vasodilator, adenosine, were determined in guinea pig aortic rings."( Endothelial-dependent and -independent responses in the thoracic aorta during endotoxic shock.
Berne, RM; Headrick, JP; Young, JS, 1991
)
0.28
" Linear regression analysis of the average for each dose from three different placentas was used to determine the dose-response relationship."( Dose-related action of gonadotropin-releasing hormone on basal prostanoid production from the human term placenta.
Forman, J; Kang, IS; Koong, MK; Siler-Khodr, TM, 1991
)
0.28
" In contrast to previous studies examining birds and viviparous lizards, no dosage induced oviposition in any of the treated females."( Effects of prostaglandin F2 alpha prostaglandin E2 and arachidonic acid on the induction of oviposition in vivo and in vitro in oviparous lizards.
DeMarco, V; Guillette, LJ; Masson, GR, 1991
)
0.28
" Mature ewes were treated during the preovulatory period with a systemic dosage of indomethacin that either consistently did (500 mg) or did not (100 mg) prevent follicular rupture."( Dose-dependent effects of indomethacin on ovulation in the sheep: relationship to follicular prostaglandin production, steroidogenesis, collagenolysis, and leukocyte chemotaxis.
McCormick, RJ; Murdoch, WJ, 1991
)
0.28
" SQ 30741 had no significant effect on mean vascular pressures in the cat, and the dose-response curve for U-46619 was shifted to the right in a parallel manner with a similar apparent maximal response."( Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed.
Feng, CJ; Hood, JS; Ibrahim, IN; Kadowitz, PJ; McMahon, TJ; Nossaman, BD, 1991
)
0.28
" In all rings, cooling caused an increase in the slope of the dose-response curve and a significant increase in the concentration of agonist required to evoke contractions, as assessed by that concentration of NE required to evoke a contraction equal to 10% of maximal (EC10)."( Cooling augments alpha 2-adrenoceptor-mediated contractions in rat tail artery.
Bowman, CJ; Harker, CT; Ousley, PJ; Porter, JM, 1991
)
0.28
" The dose-response curve of HA1077 for MLC20 phosphorylation was to the left of the tension curve produced by 40 mM K+."( Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle.
Hidaka, H; Sasaki, Y; Seto, M, 1991
)
0.28
" Dose-response relationships were determined between PGF2 alpha-IE and IOP, pupillary diameter, and refraction in ketamine-anesthetized ocular normotensive cynomolgus monkeys."( Dose-related effects of prostaglandin F2 alpha isopropylester on intraocular pressure, refraction, and pupil diameter in monkeys.
Crawford, KS; Kaufman, PL, 1991
)
0.28
"The dosage of Prostaglandin F2 alpha used until the present (100, 250 and 1000 micrograms/kg bw), in order to treat pyometra in the bitch, was accompanied with side effects such as salivation, vomiting and diarrhea."( [Use of a low dose prostaglandin F2 alpha in bitches].
Arnold, S; Casal, M; Corboz, L; Flückiger, M; Hauser, B; Hubler, M; Rüsch, P, 1991
)
0.28
" It was further demonstrated that RBPs at a higher dosage (200 micrograms/ml) was inhibitory to PGF2 alpha secretion."( The biological function of rabbit blastocyst peptides (RBPs).
Cao, YQ; Chen, YZ; Zhang, ZY; Zheng, M, 1991
)
0.28
" H-7 produced a shift to the right of the dose-response curve for the PKC activator, 12-o-tetradecanoylphorbol-13-acetate (TPA) in the case of SHR aortas, while no such shift was noted in tissues from WKY."( Effects of H-7 (protein kinase inhibitor) and phorbol ester on aortic strips from spontaneously hypertensive rats.
Iwasaki, T; Miyata, S; Morita, S; Nagai, K; Shibata, R, 1990
)
0.28
"In order to study the effect of Toxoplasma infection on hormonal levels in pregnant ewes, twenty-eight Scottish Blackface ewes were dosed orally with Toxoplasma gondii oocytes at 91 +/- 1 days of gestation."( The effect of Toxoplasma gondii infection in unvaccinated and iscom-vaccinated pregnant ewes as monitored by plasma levels of 15-ketodihydroprostaglandin F2 alpha, progesterone, and oestrone sulphate.
Buxton, D; Edqvist, LE; Fredriksson, G; Kindahl, H; Uggla, A, 1990
)
0.28
"Prostaglandin F2 alpha (PGF2 alpha), at a concentration that did not induce vascular contraction (10(-9) and 10(-10) M), potentiated the dose-response curves to norepinephrine (NE) in rat mesenteric ring segments only when the endothelium was present."( Endothelium and Ca2+ in the prostaglandin F2 alpha potentiation of vasoconstrictor responses.
Aristegui, PM; Enero, MA, 1990
)
0.28
" Increasing concentrations (10(-7)-10(-4) M) of AH6809 (which possesses negligible intrinsic agonist activity) produced parallel shifts to the right of dose-response curves to PGD2 and ZK110841."( Evaluation of ZK110841 and AH6809, an agonist and an antagonist of prostaglandin DP-receptors on human platelets, with a PGD2-responsive cell line from bovine embryonic trachea.
Hayaishi, O; Ito, S; Negishi, M; Okuda, E; Sugama, K, 1990
)
0.28
" Dose-response curves to MCh were obtained from bronchial segments before, during, and after incubation with either a subthreshold or a threshold concentration of histamine (10(-10) or 10(-8) M), the stable TxA2 analogue U46619 (10(-11) or 10(-9) M), PGD2 (5 x 10(-9) or 5 x 10(-7) M), PGF2 alpha (10(-9) or 10(-7) M), or LTC4 (10(-11) or 10(-9) M)."( Effects of inflammatory mediators on the responsiveness of isolated human airways to methacholine.
Bonta, IL; de Jongste, JC; Jongejan, RC; Kerrebijn, KF; Raatgeep, RC; Stijnen, T, 1990
)
0.28
" Dose-response testing and baseline IOP measurements were done."( Effects of prostaglandins F2 alpha, A2, and their esters in glaucomatous monkey eyes.
Bito, LZ; Camras, CB; Lee, PY; Podos, SM; Wang, RF, 1990
)
0.28
" PGF2 alpha also increased inositol phosphate formation, with a time course and dose-response consistent with its ability to increase [Ca2+]i."( Mobilization of extracellular Ca2+ by prostaglandin F2 alpha can be modulated by fluoride in 3T3-L1 fibroblasts.
Crooke, ST; Nakada, MT; Stadel, JM, 1990
)
0.28
" Topical application of exogenous PGF2 alpha and U46619 resulted in dose-dependent cerebral vasoconstriction, and the dose-response curve for each agonist was shifted to the right by the increasing concentrations of SQ29548 (10(-6)-10(-8) M)."( Effect of thromboxane A2/endoperoxide antagonist SQ29548 on the contractile response to acetylcholine in newborn piglet cerebral arteries.
Busija, DW; Wagerle, LC, 1990
)
0.28
" Dose-response studies revealed that PGF2 alpha increased the potency of insulin in granulosa cells (EC50 for insulin-stimulation of oxytocin release reduced from 141 to 13 nmol/l by 1 mumol PGF2 alpha/l), but not in luteal cells."( Chronic regulation of ovarian oxytocin and progesterone release by prostaglandins: opposite effects in bovine granulosa and early luteal cells.
McArdle, CA, 1990
)
0.28
" An additional 2 patients were excluded from the uniform evaluation because the PGF2a dosage was changed owing to a clear antiarrhythmic action in one and serious side effects in the other."( Cardiac and side effects of prostaglandin F2 alpha in patients with extrasystoles.
Hofmann, H; Lange, R; Sziegoleit, W, 1988
)
0.27
" To evaluate potential inhibitory actions, vessels were contracted by continuous LAD infusion of prostaglandin F2 alpha (PGF2 alpha) or serotonin before dose-response testing with PGE1 or nitroglycerin."( Prostaglandin E1 and nitroglycerin effects on canine epicardial conductance and distal coronary resistance vessels.
Bove, AA; Miller, WL, 1989
)
0.28
" On the day salbutamol was given, surface area under the dose-response curve to PGF2 alpha was significantly higher and the final drop of FEV1 significantly lower than those observed on days when placebo, ipratropium bromide and cromolyn sodium were given."( Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F2 alpha-induced bronchospasm.
Georgopoulos, D; Giulekas, D; Ilonidis, G; Sichletidis, L, 1989
)
0.28
" In the unblocked group, after PGF2 alpha vasoconstriction, fenoldopam infusion resulted in a dose-dependent decrease in the mean pulmonary arterial pressure with a dose-response curve characteristic for a drug-receptor interaction [Response = -1."( Effect of fenoldopam on preconstricted isolated salt-perfused rat lungs.
Bucciarelli, RL; Drummond, W; Gause, GE; Knight, ME; Polak, MJ, 1989
)
0.28
" PGF-2 alpha treatment lasted 2-26 days and dosage varied from 26."( A retrospective study of 40 cases of canine pyometra-metritis treated with prostaglandin F-2 alpha and broad-spectrum antibacterial drugs.
Gilbert, RO; Nöthling, JO; Oettle, EE, 1989
)
0.28
" However, with the pharmaceutical composition now used, the concomitant and dose-related side effects, both objective and subjective, are clearly clinically unacceptable at doses corresponding to the upper part of the dose-response curve for IOP reductions."( Effects of topically applied PGF2 alpha and its isopropylester on normal and glaucomatous human eyes.
Alm, A; Villumsen, J, 1989
)
0.28
" Dose-response curves to prostaglandin F2 alpha, (PGF2 alpha), angiotensin II (ANG II), and norepinephrine (NE) and responses to a depolarizing concentration of KCl were obtained on rings of pulmonary artery from normal rats, chronically hypoxic (10% O2 for 10 days) rats, and chronically hypoxic rats treated with cis-4-hydroxy-L-proline (cHyp), an agent that blocks collagen accumulation."( Vascular collagen affects reactivity of hypertensive pulmonary arteries of the rat.
Edelman, NH; Poiani, GJ; Riley, DJ; Tozzi, CA, 1989
)
0.28
" In trachea and right atria of the guinea-pig, tertatolol inhibited, in a concentration-dependent manner, the dose-response curves to isoproterenol; the relative potency of tertatolol was higher than that of propranolol."( Effects of tertatolol on post- and prejunctional beta adrenoceptors.
Herman, AG; Jordaens, FH; Laekeman, G; Majchrowicz, BB; Verbeuren, TJ; Zonnekeyn, LL, 1985
)
0.27
" In canine basilar arteries, endothelium removal elevated the dose-response curves to 5-HT, PGF2 alpha, and PGD2, and PGE2, but not to KCl, hemoglobin, or NE."( Effect of removal of the endothelium on vasocontraction in canine and rabbit basilar arteries.
Hongo, K; Kassell, NF; Lee, JH; Lehman, RM; Nakagomi, T; Sasaki, T; Torner, JC, 1988
)
0.27
" Progesterone in pharmacological dosage stimulates the syntheses of PGF2 alpha and of prostaglandin E2 (PGE2)."( Effects of estradiol-17 beta and progesterone on the synthesis of prostaglandin F2 alpha, prostaglandin E2 and prostaglandin I2 by fibroblasts from human endometrium in vitro.
Breckwoldt, M; Flecken, U; Neulen, J; Zahradnik, HP, 1988
)
0.27
" Cyclooxygenase inhibition with indomethacin displaced the dose-response curve to AA to the right but did not prevent the relaxant effects of the fatty acid."( Arachidonic acid-induced endothelial-dependent relaxations of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway.
Abraham, NG; Mullane, KM; Pinto, A, 1987
)
0.27
" Dose-response relationships and the magnitude of the prolactin release following domperidone or TRH varied with time."( Effects of domperidone and thyrotropin-releasing hormone on secretion of luteinizing hormone and prolactin during the luteal phase and following induction of luteal regression in sheep.
Dailey, RA; Deaver, DR; Keisler, DH, 1987
)
0.27
"Prostaglandin F2 alpha (PGF2 alpha) in a concentration that did not induce vascular contraction (10(-8) M) potentiated the dose-response curves to norepinephrine and 5-hydroxytryptamine and the contractile response induced by potassium (60 or 100 mM) in isolated mesenteric vascular bed of the rat."( Effects of prostaglandin F2 alpha on vasoconstrictor responses in the mesenteric vascular bed.
Aristegui, PM; Enero, MA, 1988
)
0.27
" Bell-shaped dose-response curves were observed for the other two monkeys."( Prostaglandin D2, a cerebral sleep-inducing substance in monkeys.
Fujita, I; Hayaishi, O; Nishino, H; Onoe, H; Oomura, Y; Ueno, R, 1988
)
0.27
" Therefore, multiple dosing with PGF2 alpha in subhuman primate eyes did not result in notable histopathological changes that would contraindicate a clinical trial in glaucoma patients."( Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. III. Histopathology.
Camras, CB; Friedman, AH; Podos, SM; Rodrigues, MM; Tripathi, BJ; Tripathi, RC, 1988
)
0.27
" Morphine altered dose-response curves for exogenous PGE2, evoking a parallel surmountable shift to the right, but did not affect the inotropic action of added PGF2 alpha."( Morphine diminishes the constancy of spontaneous uterine contractions, antagonizes the positive inotropic effects of prostaglandin E2, but not of prostaglandin F2 alpha and inhibits prostaglandin E and F outputs from the uterus of ovariectomized rats.
Chaud, MA; Faletti, A; Gimeno, AL; Gimeno, MA, 1988
)
0.27
" LGE2, AnLGE2, delta 9-LGE2 and the synthetic epimer, 8-epi-delta 9-LGE2 all induced contractions in a dose-response fashion."( Effects of E2 levuglandins on the contractile activity of the rat uterus.
Foreman, D; Miller, DB; Salomon, RG; Zuk, L, 1987
)
0.27
"Using fluorophotometry, we performed a randomized, dose-response study of the effects of a prostaglandin derivative on aqueous humor flow."( Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow.
Brubaker, RF; Kerstetter, JR; Kullerstrand, LJ; Wilson, SE, 1988
)
0.27
" The study also investigated the effects of a known adenosine antagonist, namely, the xanthine derivative 8-phenyltheophylline, which at concentrations having no intrinsic effect (10(-8) and 10(-7) M) produced a significant shift to the right only for the NECA dose-response curve."( Effects of adenosine and its analogues on porcine basilar arteries: are only A2 receptors involved?
Harper, AM; McBean, DE; Rudolphi, KA, 1988
)
0.27
"The pharmacokinetics of various non-steroidal anti-inflammatory drugs were determined to find dosage regimens by which drug concentrations known as active from human anti-inflammatory therapy could be reached and maintained in rabbits during continued administration."( Pharmacokinetics of non-steroidal anti-inflammatory drugs in male rabbits after acute and chronic administration and effect of chronic treatment on seminal prostaglandins, sperm quality and fertility.
Krüger, S; Löscher, W; Lüttgenau, H; Schlegel, W, 1988
)
0.27
"The effect of norepinephrine (NE) stimulation of near-term pregnant rabbit myometrium was studied by comparing cumulative dose-response curves for NE and NE with prazosin or indomethacin."( Effects of prazosin and indomethacin on the alpha-adrenergic stimulation of rabbit myometrium.
Barss, VA; Phillippe, M; Valles, L, 1988
)
0.27
" With this dosage a monophasic increase of portal blood flow and pressure was found with PGA1, PGE1, and PGE2, whereas PGF2 alpha caused a biphasic response: an initial decrease in portal blood flow and pressure was followed by an increase in these parameters."( Prostaglandins in diagnostic and therapeutic superior mesenteric artery pharmacoangiography.
Burgener, FA; Gutierrez, OH, 1986
)
0.27
" Prostaglandin D2 had biphasic effects on pain thresholds (hot plate and acetic acid writhing tests) when given in a dosage range of 5 ng to 5 micrograms per mouse."( Alterations in nociception after intracisternal administration of prostaglandin D2, E2 or F2 alpha to conscious mice.
Hayaishi, O; Horiguchi, S; Hyodo, M; Ueno, R, 1986
)
0.27
"Histamine concentration-effect curves were obtained using either an individual or cumulative dosing method."( Histamine contraction of isolated human airway muscle preparations: role of prostaglandins.
Bayol, A; Benveniste, J; Boullet, C; Brink, C; Cerrina, J; Haye-Legrand, I; Labat, C; Raffestin, B, 1986
)
0.27
"Plasma and knee joint synovial fluid (SF) concentration of diclofenac sodium and its hydroxylated metabolites were measured after chronic dosing with the 100 mg polymer matrix formulation."( Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation.
Dawes, PT; Fowler, PD; John, VA; Shotton, PA, 1986
)
0.27
" The EF group also had the highest failure rate, indicating that the total dosage was inadequate."( Vaginal PGE2 and intraamniotic PGF2 alpha for the termination of second trimester pregnancy.
Blattner, P; Farmakides, G; Fayemi, A; Fleischer, A; Mitchell, J; Schulman, H, 1986
)
0.27
" Multiple dosing of PGF2 alpha in monkey eyes does not appear to produce clinically significant adverse effects in either the anterior or posterior segment which would contraindicate its use in a multiple-dose clinical trial in glaucoma patients."( Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. II. Slit-lamp biomicroscopy, aqueous humor analysis, and fluorescein angiography.
Bhuyan, DK; Bhuyan, KC; Camras, CB; Master, RW; Podos, SM, 1987
)
0.27
" Dose-response studies in the same model, using four different levels of corn oil, suggest that instead of a linear relationship with respect to tumor incidence, there appears to be a threshold lying between 20 and 33% fat as calories, above which tumor promotion is manifested and below which it is not."( Fat and endocrine-responsive cancer in animals.
Cohen, LA, 1987
)
0.27
"Cumulative dose-response curves for histamine induced responses in mesometrial (ME) and antimesometrial (AME) regions of uterine horns isolated from rats at 7th, 16th and 22nd days of pregnancy, were constructed."( Is there a prostaglandin involvement in the positive inotropic action of histamine in isolated pregnant rat uterus, apparently mediated via H1-receptors activation?
Dveksler, G; Franchi, AM; Gimeno, AL; Gimeno, MF; Viggiano, M, 1987
)
0.27
" Dose-response curves for methoxamine documented its positive, but different, inotropic actions in the two groups and at the four periods of the estrous cycle."( Prostaglandin output from and the spontaneous inotropism of uterine horns isolated from underfed rats at different stages of the sex cycle. Smooth muscle contractile influences of indomethacin and of methoxamine.
Gimeno, AL; Gimeno, MA; Goldraij, A; Sterin, AB, 1987
)
0.27
" In Experiment 2, six heifers were used to investigate the in vitro dose-response relationship of 10, 20, and 40 ng PGF2 alpha/ml of medium on OT release from Day 8 luteal tissue."( Prostaglandin F2 alpha-induced release of oxytocin from bovine corpora lutea in vitro.
Abdelgadir, SE; Oldfield, JE; Stormshak, F; Swanson, LV, 1987
)
0.27
" On the other hand, the sulfonylurea (10(-4) M) shifted most points of the dose-response curve to the right for the contractile stimulation elicited by oxytocin, an influence not altered by the simultaneous presence of propranolol or sotalol."( Tolbutamide in vitro diminishes spontaneous and oxytocin-induced contractions of uterine smooth muscle from diestrous rats.
Gimeno, AL; Gimeno, MA; Goldraij, A; Sterin, AB, 1987
)
0.27
" Dose-response curves to each agonist were generated in random order, and tantalum bronchograms and simultaneous measurements of pulmonary resistance (RL) and dynamic pulmonary compliance (Cdyn) were obtained at the plateau of the response of each dose of agonist after intravenous (iv) infusion."( Distribution of airway contractile responses within the major diameter bronchi during exogenous bronchoconstriction.
Leff, AR; Mack, M; Munoz, NM; Shioya, T; Solway, J, 1987
)
0.27
" A dose-response study related to the effect of increasing concentrations of mepacrine (7."( Effects of mepacrine on uterine contractile responses.
Bade, SC; Gardner, RM, 1985
)
0.27
" On the other hand, the dose-response curve for tyramine shifted to the right in a parallel manner, and histamine-induced vasoconstriction was markedly potentiated by prolonged cold storage in a maximal increase in perfusion pressure."( Effects of prolonged cold storage on the responsiveness of isolated and perfused canine intermediate auricular artery.
Chiba, S; Ito, T, 1985
)
0.27
" In subsequent time-course and dose-response experiments, a significant effect on [3H]arachidonic acid release could be observed as early as 15 min after LHRH addition, and the lowest effective dose was 10(-8) M LHRH."( Luteinizing hormone-releasing hormone stimulates arachidonic acid release in rat granulosa cells.
Leung, PC; Minegishi, T, 1985
)
0.27
" Hexamethonium pretreatment suppressed, in a dose-response manner, the increases in blood pressure, heart rate, and rectal temperature in response to PGF2 alpha-icv."( Mechanisms involved in central cardiovascular effects of prostaglandin F2 alpha.
Feuerstein, G; Helke, CJ; Jacobowitz, DM; Kopin, IJ; Zerbe, RL, 1982
)
0.26
" Trimethaphan (10(-4)-10(-3)M) shifted the dose-response curve for norepinephrine in mesenteric arteries to the right, but failed to influence the contractile response to 25 mM KCl."( Trimethaphan is a direct arterial vasodilator and an alpha-adrenoceptor antagonist.
Harioka, T; Hatano, Y; Mori, K; Toda, N, 1984
)
0.27
" Exposure to 13-azaprostanoic acid (13-APA), 5 X 10(-5) M and 2 X 10(-4) M, for 20 min caused parallel and dose-related shifts to the right of the dose-response curves generated by all three prostanoids without affecting the contractile responses to KCl, norepinephrine, or 5-hydroxytryptamine or relaxation induced by PGI2."( Antagonism of prostanoid-induced vascular contraction by 13-azaprostanoic acid (13-APA).
Horn, PT; Kohli, JD; LeBreton, GC; Venton, DL,
)
0.13
" Group I goats served as controls, group II goats were treated (IV) with a single dose of 300 micrograms of synthetic luteinizing hormone-releasing hormone (LHRH); group III goats were treated with LHRH (similar to group II) and 24 hours later were given indomethacin (10 mg/kg; IM) which dosing was repeated every 6 hours for the next 90 hours."( Detection of ovulation in goats by blood prostaglandins concentrations.
Akinlosotu, BA; Verma, OP, 1983
)
0.27
" This provides a simple, rapid and reproducible way of obtaining linear dose-response curves by plotting times of exposures against absolute or percent increases in sRaw."( Drug effect on bronchial response to PGF2 alpha and water inhalation.
Bianco, S; Damonte, C; Robuschi, M, 1983
)
0.27
" Aerosols were generated by Wright's nebulizer and dose-response curves to histamine and methacholine constructed following preadministration of saline, prostaglandin F2 alpha or citric acid."( The influence of pretreatment with prostaglandin F2 alpha on bronchial sensitivity to inhaled histamine and methacholine in normal subjects.
Costello, JF; Dunlop, LS; Heaton, RW; Henderson, AF, 1984
)
0.27
" It was shown that (1) all tested compounds inhibited the number and severity of the intestinal mucosal lesions, however, to different extent; (2) the inhibition of the development of small intestinal mucosal damage displayed a dose-response relationship; (3) 17-aza-PGF2 alpha was found to have the most potent effect on the development of the intestinal lesions as well as on the development of gastric mucosal damage produced by ethanol."( Preventive effect of PGI2, 7-oxo-PGI2 and 17-aza-PGF2 alpha derivate on the development of indomethacin-induced intestinal mucosal damage in rats.
Beró, T; Garamszegi, M; Jávor, T; Mózsik, G, 1984
)
0.27
" Cumulative dose-response curves to oxytocin documented a greater sensitivity in uterine horns from restricted-diet rats than in those from controls or refed animals."( Dietary restriction alters the "in vitro" spontaneous or oxytocin-induced contractions of uterine smooth muscle from estrous rats. Possible participation of prostaglandins.
Gimeno, AL; Gimeno, MF; Goldraij, A; Sterin, AB, 1983
)
0.27
" The time-course of [14C]LA and [3H]AA incorporation into human leucocyte total lipids was maximal at 80-90% of the initial dose within 20-30 min of dosing the cells."( Linoleic acid and arachidonic acid metabolism in human peripheral blood leucocytes: comparison with the rat.
Crawford, MA; Cunnane, SC; Keeling, PW; Thompson, RP, 1984
)
0.27
" DSCG attenuated the acetylcholine-induced contractile responses and shifted the dose-response curve of acetylcholine downward."( Effect of disodium cromoglycate on the action of bronchoactive agents in guinea-pig tracheal strips.
Ishihara, Y; Kitamura, S; Takaku, F, 1984
)
0.27
" Recovery of immunoreactive PGE2 relative to gas chromatographic mass spectrometric dosage was 85."( Comparison of radioimmunological determinations with gas chromatography mass spectrometry dosage. A study of PGE2 and PGF2alpha in gastrointestinal fluids.
Bukhave, K; Gréen, K; Rask-Madsen, J, 1983
)
0.27
"On day 10 of each estrous cycle, 19 cycling does were given (IM) 1 of 3 dosage levels of prostaglandin F2 alpha (PGF2 alpha) or saline solution."( Induction of luteolysis in goats with prostaglandin F2 alpha.
Bretzlaff, KN; Hill, A; Ott, RS, 1983
)
0.27
" This constituted an ED50 abortifacient dosage schedule of PGF2 alpha."( Antiabortifacient action of dibenzyloxyindanpropionic acid in mice.
Azzolin, G; Del Vecchio, FR; Rahwan, RG; Witiak, DT, 1983
)
0.27
" To define the relationship between OT sensitivity and uterine PG production, we measured uterine sensitivity to OT by a quantitative dose-response procedure in rats on Days 19, 20, 21 and 22 of pregnancy and monitored uterine and placental tissue concentrations of PGF2 alpha and PGE2."( Uterine and placental prostaglandins and their modulation of oxytocin sensitivity and contractility in the parturient uterus.
Chan, WY, 1983
)
0.27
" Both PGE1 and PGF2 alpha showed a dose-response curve of Michaelis-Menten type."( Effect of prostaglandins E1, E2, and F2 alpha on the electric activity of the sphincter of Oddi in living rabbit.
Martinez, E; Sarles, JC, 1983
)
0.27
" More detailed dose-response studies revealed that the I50 for inhibition of PG production by dexamethasone was less than 10 nM, thus indicating that the steroid effect probably involved high affinity glucocorticoid receptors."( Prostaglandin production by human trabecular cells: in vitro inhibition by dexamethasone.
Mitchell, MD; Polansky, JR; Weinreb, RN, 1983
)
0.27
" Since changes in tracheal pressure did not show a significant dose-response relationship, the RARs responding to PGF2 alpha seemed to be stimulated by a direct mechanism."( Effect of prostaglandin F2 alpha on pulmonary rapidly-adapting-receptors in the guinea pig.
Bergren, DR; Gustafson, JM; Myers, DL, 1984
)
0.27
" In dose-response studies in normal subjects, prostaglandin D2 caused a significant (20 +/- 6 per cent) fall in specific airway conductance after the two highest concentrations (250 and 500 micrograms per milliliter), whereas prostaglandin F2 alpha had no effect."( The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men.
Hardy, CC; Holgate, ST; Robinson, C; Tattersfield, AE, 1984
)
0.27
" Moreover, in vitro cumulative dose-response curves for the contractile effect of these three PGs, on identical oviductal segments, were constructed."( Role of endogenous and exogenous prostaglandins on the contractile functioning of isolated sow (Sus scrofa) oviducts.
Chaud, M; Franchi, AM; Gimeno, AL; Gimeno, MF; Gonzalez, ET; Viggiano, M, 1984
)
0.27
" Statistically significant dose-response relationships were always observed, but with one exception, no differences were found between the contractile responses (norepinephrine, serotonin, prostaglandin F2 alpha) or the dilating responses (papaverine) in diabetic vs normal mice."( Microvascular responses of intermediate-size arterioles on the cerebral surface of diabetic mice.
Levasseur, JE; Rosenblum, WI, 1984
)
0.27
" Thus, the effect of prostaglandins on GE and SIT depends upon the dosage and route of administration as well as type of prostaglandin used."( The effects of PGF2 alpha, PGE2 and 16, 16 dimethyl PGE2 on gastric emptying and small intestinal transit in rat.
Rush, BD; Ruwart, MJ, 1984
)
0.27
" Cumulative dose-response curves for H, in strips isolated from proestrous rats, showed that the agonist inhibited, at all the concentrations tested, spontaneous myometrial contractions, evoking a maximum effect (100% inhibition) at 10(-5)M."( Prostaglandins and ovarian factors as modulators of the negative inotropic action of histamine in the isolated rat uterus.
Dveksler, G; Franchi, AM; Gimeno, AL; Gimeno, MF; Viggiano, M, 1984
)
0.27
" Inhalation dose-response curves to histamine diphosphate were constructed on two separate occasions using the same standardised technique."( Induction of bronchial hypersensitivity: evidence for a role for prostaglandins.
Bevan, C; Parrish, RW; Smith, AP; Walters, EH, 1981
)
0.26
" Dose-response contractile activity to PGs with and without gassing was explored."( Does hypoxia selectively stimulate the generation of prostaglandin E1 by the isolated rat uterus?
Borda, ES; Chaud, M; Gimeno, AL; Gimeno, MF; Lazzari, M, 1981
)
0.26
" Bronchoconstriction was produced by close intraarterial injection of histamine, acetylcholine, serotonin, or PGF2 alpha at a dosage of 10 microgram each."( [Role of vagus nerves in bronchoconstriction induced by chemical mediators].
Goto, K; Hayakawa, H; Hosokawa, T; Kitagawa, H; Kobayashi, N; Misawa, M; Yanaura, S, 1982
)
0.26
" Four bitches treated between Days 21-42 after second service did not produce pups irrespective of dosage and duration of administration."( Clinical experience with prostaglandin F2 alpha THAM as a luteolytic agent in pregnant and non-pregnant bitches.
Oettlé, EE, 1982
)
0.26
" The aim of this study was to investigate the rate of eicosanoid biosynthesis after oral dosing with nabumetone in nine healthy subjects."( Effects of nabumetone on prostanoid biosynthesis in humans.
Cipollone, F; Cuccurullo, F; Ganci, A; Greco, A; Panara, MR; Patrignani, P; Patrono, C, 1995
)
0.29
" This dose increased plasma selenoprotein P substantially, and a dose-response was present."( Pathogenesis of diquat-induced liver necrosis in selenium-deficient rats: assessment of the roles of lipid peroxidation and selenoprotein P.
Awad, JA; Burk, RF; Cockell, KA; Hill, KE; Kato, T; Lyons, PR; Morrow, JD, 1995
)
0.29
" [4-Threonine, 7-glycine]oxytocin, a highly potent and selective uterotonic oxytocin analogue, had no detectable prostaglandin-releasing activity at a dosage 30 times higher than oxytocin."( Agonist and antagonist specificities of decidual prostaglandin-releasing oxytocin receptors and myometrial uterotonic oxytocin receptors in pregnant rats.
Chan, WY; Chen, DL; Manning, M, 1994
)
0.29
" Clonogenic cell survival after irradiation showed a typical exponential radiation dose-response curve with a fairly broad initial shoulder."( Radiation reduces cyclooxygenase activity in cultured human endothelial cells at low doses.
Dewit, L; Koomen, GC; van Mourik, JA; Verheij, M, 1994
)
0.29
" The slopes of the dose-response functions to CPA or DPMA were not significantly altered in the normally perfused circumflex vascular bed."( Ischaemia/reperfusion selectively attenuates coronary vasodilatation to an adenosine A2- but not to an A1-agonist in the dog.
Cox, BF; Greenland, BD; Merkel, LA; Perrone, MH, 1994
)
0.29
" In experiment 3, explants were incubated in the presence of oxytocin or arginine vasopressin at 10(-9) to 10(-6) M to establish dose-response curves for the activation of PLC and release of PGF2 alpha."( Cellular mechanisms mediating the stimulation of ovine endometrial secretion of prostaglandin F2 alpha in response to oxytocin: role of phospholipase C and diacylglycerol.
Brockman, JA; Hayes, SH; Lee, JS; Lowberger, LL; Silvia, WJ; Trammell, DS, 1994
)
0.29
" The addition of increasing concentrations of phloretin caused progressive shifts of the dose-response curves of PGF2 alpha to the right."( Phloretin as an antagonist of prostaglandin F2 alpha receptor in cultured rat astrocytes.
Baba, A; Ishibashi, T; Kitanaka, J, 1993
)
0.29
" By pretreatment with 13-azaprostanoic acid (13-APA), a TXA2/endoperoxide receptor antagonist, the dose-response curve of BPS in the veins was shifted to the right."( The contractile mechanism of beraprost sodium, a stable prostacyclin analog, in the isolated canine femoral vein.
Ishikawa, M; Namiki, A, 1994
)
0.29
" Patients in both groups received oxytocin to a maximum dosage of 120 mU per minute if they had not aborted 18 hours after the original administration of either prostaglandin regimen."( Mid-trimester termination of pregnancy--a randomised controlled trial of two prostaglandin regimens.
Pienaar, MP; Steyn, DW, 1993
)
0.29
" Identical dose-response curves were produced by PGF2 alpha in arteries from OH and LN dogs."( Decreased potency of contraction to alpha-adrenoceptor stimulation in renal arteries from obese hypertensive dogs.
Granger, JP; Ratz, PH; West, DB, 1993
)
0.29
" The study showed that it was not possible to affect the time period to completed uterine involution, not even when a very intensive drug dosage was used."( The effect of intensive flunixin treatment during the postpartum period in the bovine.
Fredriksson, G; Odensvik, K, 1993
)
0.29
" Dose-response curves of the development of tension in the hyperplastic artery to various agonists (K+, PGF2 alpha, norepinephrine) shifted upward the curves for the control artery."( Intimal hyperplasia enhances myosin phosphorylation in rabbit carotid artery.
Azuma, H; Sasaki, Y; Seto, M; Yano, K, 1993
)
0.29
" After pretreatment of myometrial explants with a cyclo-oxygenase inhibitor (indomethacin), the PGF2 alpha dose-response curve was shifted to the left and a maximal level of PGF2 alpha-induced IP accumulation was reached."( Prostaglandin F2 alpha stimulates inositol phosphate production in human pregnant myometrium.
Breuiller-Fouche, M; Ferre, F; Geny, B; Maka, FD, 1993
)
0.29
" Dose-response relations to PGD2 showed three distinct patterns: 1) a dose-dependent decrease in short-circuit current (Isc) at lower concentrations followed by a dose-dependent increase at higher concentrations; 2) dose-dependent decreases, with no increase even at the highest concentrations tested; and 3) dose-dependent increases in Isc, with no decreases at any concentration."( Biological activity of metabolites of PGD2 on canine proximal colon.
Betti, PA; Rangachari, PK, 1993
)
0.29
" The results indicate that oral dosing of flunixin, in the form of granules, can be an alternative to intravenous administration for therapeutic use in cattle."( Pharmacokinetics of flunixin and its effect on prostaglandin F2 alpha metabolite concentrations after oral and intravenous administration in heifers.
Odensvik, K, 1995
)
0.29
"Flunixin meglumine at a dosage of 500 mg/animal, administered IV every 8 hours, is ineffective in modulating uterine PGF2 alpha secretion during cloprostenol-induced abortion."( Effect of flunixin meglumine on endogenous prostaglandin F2 alpha secretion during cloprostenol-induced abortion in mares.
Daels, PF; Kindahl, H; Mohammed, HO; Odensvik, K, 1995
)
0.29
" The rats were fed a basal diet containing either 12% olive oil, 12% safflower oil, 12% perilla oil, 6% perilla oil plus 6% olive oil, or 3% perilla oil plus 9% olive oil for 5 weeks, starting 1 week before the first dosing of AOM."( Suppressing effect of perilla oil on azoxymethane-induced foci of colonic aberrant crypts in rats.
Kawamori, T; Komaki, C; Mori, H; Moriwaki, H; Muto, Y; Okuno, M; Onogi, N; Tanaka, T, 1996
)
0.29
" Heparinized whole blood samples were drawn from healthy volunteers, 48 h following oral dosing with aspirin 300 mg to suppress platelet cyclo-oxygenase activity."( Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F2-isoprostane formation.
Ciabattoni, G; di Giamberardino, M; Greco, A; Maclouf, J; Panara, MR; Patrignani, P; Patrono, C; Rotondo, MT; Santini, G; Sciulli, MG, 1996
)
0.29
" Repeated doses of PGF2 alpha-TS or PGF2 alpha-IE did not significantly affect the accommodative response to pilocarpine, while pilocarpine did not alter the approximately 10 mmHg ipsilateral IOP fall induced by repeated dosing of PGF2 alpha-TS or PGF2 alpha-IE."( PGF2 alpha/pilocarpine interactions on IOP and accommodation in monkeys.
Kaufman, PL; Millar, JC, 1995
)
0.29
"We performed the following studies: (1) a cross-sectional comparison of smokers and control subjects, (2) an examination of the dose-response relationship, (3) an exploration of the effect of smoking cessation (3 weeks) and nicotine patch supplementation, (4) the effect of aspirin consumption, and (5) the effects of 5 days' dosing with vitamin E (100 and 800 U), vitamin C (2 g), and their combination."( Modulation of oxidant stress in vivo in chronic cigarette smokers.
Delanty, N; FitzGerald, GA; Lawson, JA; Reilly, M, 1996
)
0.29
"5 kg) were infused with randomly selected doses of U46,619 and of 8-epi-PGF2 alpha to describe dose-response curves plotting pulmonary vascular resistance (PVRi) against dose."( Effects of 8-epi-prostaglandin F2 alpha and U46,619 on pulmonary hemodynamics in piglets.
Norberg, M; Thibeault, DW; Truog, WE, 1997
)
0.3
" By comparing the time course of stimulation and dose-response relationships between PGF2 alpha and PLC activity, it appears that oxytocin may stimulate PGF2 alpha secretion by activating PLC."( Cellular mechanisms by which oxytocin stimulates uterine PGF2 alpha synthesis in bovine endometrium: roles of phospholipases C and A2.
Burns, PD; Graf, GA; Hayes, SH; Silvia, WJ, 1997
)
0.3
" The arteries were precontracted with PGF2alpha (3 microM) and cumulative dose-response curves to either NECA itself, or the selective A2A agonists, 2-[4-2(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosi ne (CGS 21680) and 2-hexynyl-5'-N-ethylcarboxamidoadenosine (2HE-NECA) were obtained."( Prolonged exposure to 5'-N-ethylcarboxamidoadenosine (NECA) does not affect the adenosine A2A-mediated vasodilation in porcine coronary arteries.
Conti, A; Lozza, G; Monopoli, A, 1997
)
0.3
" However, the 4 mg/day dosage delayed the time to peak PGFM (32."( Effects of exogenous recombinant ovine interferon tau on circulating concentrations of progesterone, cortisol, luteinizing hormone, and antiviral activity; interestrous interval; rectal temperature; and uterine response to oxytocin in cyclic ewes.
Bazer, FW; Chen, P; Fleming, JG; Green, CN; Harms, PG; Joyce, MM; Ott, TL; Spencer, TE; Welsh, TH; Zhu, D, 1997
)
0.3
"Three groups of five beagle bitches were treated three times a day with natural prostaglandin F2 alpha (PGF2 alpha) at a dosage of either 20 micrograms kg-1 bodyweight (days 5-8 of metoestrus), 50 micrograms kg-1 bodyweight (days 5-11 of metoestrus) or 20 micrograms kg-1 bodyweight after detection of pregnancy (days 20-21 after ovulation) for 7 days."( Effects of low doses of prostaglandin F2 alpha during the early luteal phase before and after implantation in beagle bitches.
Günzel-Apel, AR; Hoppen, HO; Lange, K; Mischke, R; Nolte, I, 1997
)
0.3
" Urinary 8-epi-PGF2 alpha was unchanged after 2-week dosing with aspirin and indobufen despite complete suppression of TX metabolite excretion."( In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.
Alessandrini, P; Bon, GB; Bucciarelli, T; Ciabattoni, G; Cipollone, F; Costantini, F; Davi, G; Mezzetti, A; Minotti, G; Patrono, C, 1997
)
0.3
" Outflow facility was measured in six normal monkeys 3 hours prior to dosing and 1 hour after unilateral dosing with either drug."( A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.
Kitazawa, Y; Podos, SM; Serle, JB; Wang, RF,
)
0.13
" Three dosing regimes were used; twice (n = 2), thrice (n = 4) and four times daily (n = 6)."( The effect on luteolysis by intensive oral administration of flunixin granules in heifers.
Gustafsson, H; Kindahl, H; Odensvik, K, 1998
)
0.3
" Moreover, the minute dosage used eludes potentially complicating side effects."( Intrauterine irrigation with prostaglandin F2-alpha for management of severe postpartum hemorrhage.
Bar-Am, A; Daniel, Y; Gull, I; Jaffa, A; Kupferminc, MJ; Lessing, JB; Shenhav, M, 1998
)
0.3
" It is concluded that (1) maternal infusion of ACTH1-24 at the dosage used does not induce labour in guinea-pigs, and (2) ACTH1-24 does not cross the placenta."( Effect of maternal infusion of adrenocorticotrophin1-24 (ACTH1-24) on parturition in guinea-pigs near term.
Schellenberg, JC, 1997
)
0.3
" Female Sprague-Dawley rats were dosed with diethylnitrosamine (15 mg/kg) at 24 h of age."( Effect of dietary lipid on gamma-glutamyl transferase-positive foci during hepatocarcinogenesis in rats.
Chen, HW; Ko, JJ; Lii, CK, 1998
)
0.3
" pD2 values and maximum percentage increases in contractile tension were derived from dose-response curves to 10(-9) to 10(-5) mol/L PGE2 and PGE2 alpha, and 10(-11) to 10(-7) mol/L oxytocin."( In vivo administration of nimesulide, a selective PGHS-2 inhibitor, increases in vitro myometrial sensitivity to prostaglandins while lowering sensitivity to oxytocin.
Baguma-Nibasheka, M; Nathanielsz, PW,
)
0.13
" The dose-response curves of vasoconstriction to phenylephrine and prostaglandin F2alpha were obtained in healthy male volunteers."( Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity.
Kimura, M; Kosuge, K; Nakashima, M; Nishimoto, M; Ohashi, K; Umemura, K, 1998
)
0.3
"The ACEIs shifted the dose-response curve of phenylephrine to the right and raised the median effective dose (ED50; 189."( Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity.
Kimura, M; Kosuge, K; Nakashima, M; Nishimoto, M; Ohashi, K; Umemura, K, 1998
)
0.3
" 8-iso-PGF2alpha was unchanged after 2-week dosing with aspirin and indobufen despite profound suppression of TXM excretion."( In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.
Bucciarelli, T; Capani, F; Ciabattoni, G; Consoli, A; Costantini, F; Davì, G; Falco, A; Mezzetti, A; Patrono, C; Pennese, E; Santarone, S; Vitacolonna, E, 1999
)
0.3
" After reducing perfusion pressure to 20 mmHg for 30 min and reperfusing at 80 mmHg, the dose-response curve to U46619 was unaffected."( The vasoconstrictor effect of 8-epi prostaglandin F2alpha in the hypoxic rat heart.
Kromer, BM; Tippins, JR, 1999
)
0.3
" Dose-response curves to noradrenaline-induced vasoconstriction were performed before and after continuous infusions of two different PAF-receptor antagonists (WEB 2086 and yangambin) and of the phospholipase A2 inhibitor mepacrine."( Involvement of platelet-activating factor in the modulation of vascular tone in the isolated perfused rabbit kidney.
Aimbire, F; Cailleaux, S; Cordeiro, RS; Lopes-Martins, RA; Tibiriçá, E, 1999
)
0.3
" Urinary iPF2a-III increased in a time- and dosage-dependent manner after dosing with alcohol, with the peak urinary iPF2a-III excretion correlating with the rise in blood alcohol."( Alcohol-induced generation of lipid peroxidation products in humans.
Barry, OP; Burke, A; FitzGerald, GA; Lawson, JA; Lucey, MR; Meagher, EA; Rokach, J, 1999
)
0.3
" Coronary epicardial and arteriolar endothelial function was determined by a dose-response relaxation to bradykinin (10(-11) to 10(-6) mol/L), in all groups and in pigs maintained on a normal diet."( Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro.
Best, PJ; Holmes, DR; Lerman, A; Lerman, LO; Richardson, D; Romero, JC, 1999
)
0.3
"To determine the efficacy of reducing the dosage of GnRH used in a protocol for synchronization of ovulation and timed AI, primiparous and multiparous lactating Holstein cows (n = 237) were randomly assigned to 1 of 2 treatment groups."( Efficacy of decreasing the dose of GnRH used in a protocol for synchronization of ovulation and timed AI in lactating dairy cows.
Fricke, PM; Guenther, JN; Wiltbank, MC, 1998
)
0.3
" Recommended dosing is once daily at bedtime."( Prostaglandin analogs in the treatment of glaucoma.
Camras, CB; Hejkal, TW, 1999
)
0.3
" That the rise in plasma epicatechin levels was functionally significant is suggested by observations of trends for dose-response increases in the plasma antioxidant capacity and decreases in plasma lipid oxidation products."( A dose-response effect from chocolate consumption on plasma epicatechin and oxidative damage.
Ensunsa, JL; Fraga, CG; Holt, RR; Keen, CL; Schmitz, HH; Schramm, DD; Wang, JF, 2000
)
0.31
"5 g resting tensions, NOS inhibitors shifted the ACh dose-response curve to the right."( Mechanical stretch reveals different components of endothelial-mediated vascular tone in rat aortic strips.
Bani, D; Ciuffi, M; Failli, P; Franchi-Micheli, S; Mazzetti, L; Zilletti, L, 2000
)
0.31
" This prospective study included 59 NTG and 20 POAG patients treated with the following four dosing regimens of latanoprost: patients on no previous medication received latanoprost as initial therapy (Group 1, n=31), patients on beta-blocker therapy received latanoprost as adjunctive therapy (Group II, n=9), patients on unoprostone monotherapy were switched to latanoprost monotherapy (Group III, n=14), and patients previously on dual therapy with isopropyl unoprostone and beta-blocker were switched to a combined treatment of latanoprost and beta-blocker (Group IV, n=25)."( Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma.
Kitazawa, Y; Murase, H; Tamada, Y; Taniguchi, T; Yamamoto, T, 2001
)
0.31
" At a dosage rate of 100 microg, lipopolysaccharides are not absorbed by the healthy endometrium and do not alter the oestrous cycle length."( Some aspects of immunology of the bovine uterus related to treatments for endometritis.
Dhaliwal, GS; Murray, RD; Woldehiwet, Z, 2001
)
0.31
"003% w/w) using a twice-daily dosing regime."( 3-Oxa-15-cyclohexyl prostaglandin DP receptor agonists as topical antiglaucoma agents.
Bishop, JE; Conrow, RE; Crider, JY; Dean, WD; DeWolf, KA; Hellberg, MR; Klimko, PG; McLaughlin, MA; Pierce, DR; Sallee, VL; Selliah, RD; Severns, BS; Sharif, NA; Sproull, SJ; Williams, GW; Zinke, PW, 2002
)
0.31
" Spinal administration of PGE2 produced a bi-directional, dose-response effect on thermally-evoked responses of both WDR and NS neurons when prostaglandin-induced changes in background discharges were controlled for."( Spinal administration of prostaglandin E(2) or prostaglandin F(2alpha) primarily produces mechanical hyperalgesia that is mediated by nociceptive specific spinal dorsal horn neurons.
Randich, A; Spraggins, DS; Turnbach, ME, 2002
)
0.31
" Oxytocin binding was suppressed by progesterone at every dosage tested."( Direct inhibitory effect of progesterone on oxytocin-induced secretion of prostaglandin F(2alpha) from bovine endometrial tissue.
Bogacki, M; Kotwica, J; Rekawiecki, R; Silvia, WJ, 2002
)
0.31
" Isolated rings of the thoracic aorta were obtained from rats immediately or 24 h after in vivo exposure to 60 min of hyperoxia (>95% O2), and the in vitro dose-response to phenylephrine (PHE), prostaglandin F2alpha (PGF2alpha) and endothelin-1 (ET-1), acetylcholine (Ach) and sodium nitroprusside (SNP) was assessed."( Exposure of rats to hyperoxia enhances relaxation of isolated aortic rings and reduces infarct size of isolated hearts.
Eha, I; Elfström, P; Kals, J; Starkopf, J; Taal, G; Tähepõld, P; Talonpoika, A; Vaage, J; Valen, G, 2002
)
0.31
" No PGF(2alpha) dose-response pattern was observed and overall rates of luteal regression (progesterone <1."( Efficacy of PGF(2alpha) to synchronize estrus in water buffalo cows (Bubalus bubalis) is dependent upon plasma progesterone concentration, corpus luteum size and ovarian follicular status before treatment.
Brito, LF; Kastelic, JP; Marson, EP; Satrapa, R, 2002
)
0.31
" In this study, the effects of low intracameral doses (20 ng and 50 ng) of calcitonin gene-related peptide, prostaglandin F(2alpha), and simultaneous dosing of both, on the outflow facility were studied in the rabbit."( Effect of simultaneous CGRP and PGF(2alpha) on the outflow facility in the rabbit eye.
Alajuuma, P; Alaranta, S; Oksala, O; Palkama, A; Uusitalo, H,
)
0.13
" A portal perfusion pressure dose-response curve to methoxamine was performed in control and cirrhotic rat livers preincubated with vehicle, the nitric oxide synthase blocker N(G)-nitro-L-arginine (L-NNA), indomethacin cyclooxygenase (COX) inhibitor, L-NNA + indomethacin, or the thromboxane (TX) A(2) receptor blocker SQ 29,548."( Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers.
Abraldes, JG; Bosch, J; Bragulat, M; Corominola, H; García-Pagán, JC; Graupera, M; Peralta, C; Rodés, J, 2003
)
0.32
"The discovery of a functional single-nucleotide polymorphism in the cyclooxygenase 1 locus may ultimately improve the safe and effective use of acetylsalicylic acid by better tailoring of dosage with an individual's genetic variation."( Genetic variation in cyclooxygenase 1: effects on response to aspirin.
Halushka, MK; Halushka, PV; Walker, LP, 2003
)
0.32
" Dose-response curves were constructed for the chorion cell cultures with CRH or 8-bromo-cAMP."( Regulation of 15-hydroxy prostaglandin dehydrogenase by corticotrophin-releasing hormone through a calcium-dependent pathway in human chorion trophoblast cells.
Challis, JR; McKeown, KJ, 2003
)
0.32
" In the dose-response study, the maximum increase in plasma vitamin C occurred 3 h postdose in both the men and the women."( Effect of orange juice intake on vitamin C concentrations and biomarkers of antioxidant status in humans.
Cano, MP; de Ancos, B; Granado, F; Martín, A; Olmedilla, B; Plaza, L; Sánchez-Moreno, C, 2003
)
0.32
" However, unoprostone, but not brimonidine, decreased IOP over the complete 12-hour daytime dosing cycle."( The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
Day, DG; Jenkins, J; Stewart, JA; Stewart, WC, 2004
)
0.32
" Dose-response as well as temporal-response experiments were performed, and PGF(2 alpha) levels were determined by radioimmunoassay (RIA)."( Pronounced induction of testicular PGF(2 alpha) and suppression of testosterone by cadmium-prevention by zinc.
Gunnarsson, D; Nordberg, G; Selstam, G; Svensson, M, 2004
)
0.32
" Topical ocular dosing of AL-12182, the isopropyl ester prodrug of the potent agonist 13, lowered intraocular pressure in the monkey by 40% accompanied by minimal conjunctival hyperemia in the rabbit."( AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey.
Conrow, RE; Dean, WD; Delgado, P; Earnest, D; Gaines, MS; Haggard, KS; Hellberg, MR; Klimko, PG; McLaughlin, MA; Scott, DA; Selliah, RD; Sharif, NA; Williams, GW, 2004
)
0.32
" In the dose-response study, the maximum increase in plasma vitamin C occurred 4 hours postdose."( Pulsed electric fields-processed orange juice consumption increases plasma vitamin C and decreases F2-isoprostanes in healthy humans.
Cano, MP; de Ancos, B; Elez-Martínez, P; Granado, F; Martín, A; Martín-Belloso, O; Olmedilla, B; Plaza, L; Sánchez-Moreno, C, 2004
)
0.32
"15% unoprostone isopropyl solution induced no significant ocular side effects in normal cats when dosed over a 10-day treatment period."( The effects of bimatoprost and unoprostone isopropyl on the intraocular pressure of normal cats.
Bartoe, JT; Brightman, AH; Davidson, HJ; Horton, MT; Jung, Y,
)
0.13
" The dose-response relationship of P4 to OT binding was examined."( Nongenomic action of progesterone inhibits oxytocin-induced phosphoinositide hydrolysis and prostaglandin F2alpha secretion in the ovine endometrium.
Bishop, CV; Stormshak, F, 2006
)
0.33
"In the feline iris, AGN 204396 produced a rightward shift of the dose-response curves for prostamide F2alpha and the prostamide F2alpha analog bimatoprost but did not block the effects of PGF2alpha and synthetic FP receptor agonists."( Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.
Burk, RM; Donde, Y; Krauss, AH; Landsverk, K; Liang, Y; Nieves, AL; Protzman, CE; Struble, C; Wang, JW; Woodward, DF, 2007
)
0.34
" To determine the proper dosage for a GnRH-antagonist (Cetrorelix), 12 animals in three groups of four female marmosets were treated with two different dosages and a sham dosage."( GnRH-antagonist mediated down-regulation of the estrous cycle in marmosets.
Kuhlmann, M; Luetjens, CM; Wesselmann, R, 2006
)
0.33
"By oral or intravenous dosing AS604872 reduced markedly and dose-dependently the spontaneous uterine contractions in late-term pregnant rats at gestational days 19-21."( Tocolytic effect of a selective FP receptor antagonist in rodent models reveals an innovative approach to the treatment of preterm labor.
Chollet, A; Cirillo, R; Tos, EG, 2007
)
0.34
" It was concluded that the influence of CLA on lipid autoxidation is dependent on supplement type, supplement dosage and chosen indicator, including its tissue and determination methodology."( Supplementation with commercial mixtures of conjugated linoleic acid in association with vitamin E and the process of lipid autoxidation in rats.
Botelho, AP; de Oliveira, AC; Santos-Zago, LF, 2007
)
0.34
"Neither therapeutic dosage of nitrovasodilators nor the development of tolerance correlates with nitrate groups in these molecules."( Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate.
Daiber, A; Glusa, E; Koenig, A; Konter, J; Lange, K; Lehmann, J; Stalleicken, D, 2007
)
0.34
" Overall, injection of Cloprostenol at this dosage and frequency increased libido, semen volume, sperm concentration and plasma testosterone concentration in low libido Holstein bulls."( Cloprostenol injection improves reproductive characteristics in low libido Iranian Holstein bulls.
Javaremi, AN; Masoumi, R; Nabizadeh, H; Towhidi, A; Zhandi, M, 2008
)
0.35
"We investigated changes in serum biomarkers of vascular function after short-term, continuous sildenafil dosing in men with type 2 diabetes with erectile dysfunction."( Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction.
Bivalacqua, TJ; Burnett, AL; Jin, L; Musicki, B; Strong, TD; Trock, BJ, 2009
)
0.35
" Among women with a BMI < or = 23, breast cancer risk was reduced with increasing 15-F(2t)-IsoP levels in a dose-response manner (P for trend = ."( Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study.
Cai, H; Cai, Q; Chow, WH; Dai, Q; Gao, YT; Li, H; Milne, G; Rothman, N; Shu, XO; Wen, W; Xiang, Y; Yang, G; Zheng, W, 2009
)
0.35
" Longitudinal myometrial strips isolated from each animal were pretreated with either oxytocin 10(-8) mol/L (experimental groups) or physiological salt solution (control groups) for 1 hour in organ bath chambers, and then subjected to a dose-response study with oxytocin (n = 28), ergonovine (n = 16), or PGF(2 alpha) (n = 16), with cumulative increases in the organ bath concentrations from 10(- 10) to 10(-5) mol/L."( Oxytocin pretreatment of pregnant rat myometrium reduces the efficacy of oxytocin but not of ergonovine maleate or prostaglandin F 2 alpha.
Balki, M; Carvalho, JC; Cristian, AL; Kingdom, J, 2010
)
0.36
" Analyses using interviewer ratings on the Hamilton Scale revealed that, within the depressed cohort, there was no significant association between the severity of symptoms and levels of 8-iso-PGF(2α), suggesting this is a threshold rather than a dose-response relationship."( Depression and oxidative damage to lipids.
Forlenza, MJ; Miller, GE; Yager, S, 2010
)
0.36
" When the erythropoietin dosage was stable throughout, only the NAC group had a significant increase in hematocrit, accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density lipoprotein."( N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients.
Chiang, CK; Chien, CT; Hsu, SP; Yang, SY, 2010
)
0.36
" Regardless of dosage (1."( Effects of adrenocorticotropic hormone and flunixin meglumine on pregnancy retention in beef cows.
Geary, TW, 2012
)
0.38
" In this variable-dose vegetable study, a dose-response for plasma carotenoids was demonstrated without significant change in oxidative stress and inflammation in overweight, postmenopausal women."( Increasing the vegetable intake dose is associated with a rise in plasma carotenoids without modifying oxidative stress or inflammation in overweight or obese postmenopausal women.
Crane, TE; Kroggel, MA; Kubota, C; Thomson, CA; Wertheim, BC; West, JL, 2011
)
0.37
" However, the IOP-lowering effects of unoprostone do not compare with other commercially available prostanoids and it has the disadvantage of a twice-daily rather than once-daily dosing regimen."( Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease.
Harms, NV; Toris, CB, 2013
)
0.39
" Targeting of multiple mechanisms in combination therapies has proven effective both clinically and commercially although potential improvements with regards to efficacy, tolerability and dosing frequency remain."( A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
Frieman, B; Hegde, SS; Hill, CM; Jiang, L; Kintz, S; Long, DD; Marquess, DG; Purkey, H; Shaw, JP; Steinfeld, T; Wilson, MS; Wrench, K, 2013
)
0.39
"Polycyclic aromatic hydrocarbons (PAHs) are known to induce reactive oxygen species and oxidative stress, but the dose-response relationships between exposure to PAHs and oxidative stress levels have not been established."( Dose-response relationships of polycyclic aromatic hydrocarbons exposure and oxidative damage to DNA and lipid in coke oven workers.
Deng, Q; Guan, L; Guo, H; Hu, D; Huang, K; Kuang, D; Wu, T; Zhang, W; Zhang, X, 2013
)
0.39
" These miRNAs were associated with a dose-response increase in 8-OH-dG (β > 0), and with a dose-response decrease in 8-iso-PGF2α (β < 0), especially in workers with lower PAHs exposure levels, in nonsmokers, and in nondrinkers."( Polycyclic aromatic hydrocarbons-associated microRNAs and their interactions with the environment: influences on oxidative DNA damage and lipid peroxidation in coke oven workers.
Dai, X; Deng, H; Deng, Q; Feng, J; Guo, H; Hu, D; Huang, K; Huang, S; Kuang, D; Wang, T; Wu, T; Zhang, W; Zhang, X, 2014
)
0.4
" In this study, the dose-response effect of recombinant bovine IFN-τ (rbIFN-τ) on prostaglandin (PG) production by buffalo endometrial stromal cells cultured in vitro was studied."( IFN-τ acts in a dose-dependent manner on prostaglandin production by buffalo endometrial stromal cells cultured in vitro.
Agarwal, SK; Chethan, SG; Kumar, N; Nongsiej, J; Rakesh, HB; Singh, RP; Singh, SK, 2014
)
0.4
" Results in the BET group suggest that investigation into types, dose, and dosage schedule of glucocorticoids may facilitate placental maturation."( Localization of TGF-β and TGF-β receptor in bovine term placentome and expression differences between spontaneous and induced parturition.
Fujii, T; Fukuda, S; Hirayama, H; Kageyama, S; Koyama, K; Naito, A; Sawai, K, 2015
)
0.42
"024%, dosed QD for 14 days, significantly lowered mean IOP in healthy Japanese subjects during the entire 24-h period."( Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.
Araie, M; Sforzolini, BS; Vittitow, J; Weinreb, RN, 2015
)
0.42
"To investigate the effect of initial insulin dosage on blood glucose (BG) dynamics, β-cell protection, and oxidative stress in type 1 diabetes mellitus."( Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus.
Cao, B; Gong, C; Gu, Y; Li, W; Liang, X; Liu, M; Meng, X; Su, C; Wang, Y; Wei, L; Wu, D, 2017
)
0.46
" The actual insulin dosage over the 3 wk, frequency of hypoglycemia on wk 1 and 2, and median BG at the end of wk 1 differed significantly, but not 8-iso-PGF2α and the honeymoon period in the three groups."( Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus.
Cao, B; Gong, C; Gu, Y; Li, W; Liang, X; Liu, M; Meng, X; Su, C; Wang, Y; Wei, L; Wu, D, 2017
)
0.46
"Differences in initial insulin dosage produced different BG dynamics in wk 1, equivalent BG dynamics on wk 2 and 3, but had no influence on short- and long-term BG control and honeymoon phase."( Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus.
Cao, B; Gong, C; Gu, Y; Li, W; Liang, X; Liu, M; Meng, X; Su, C; Wang, Y; Wei, L; Wu, D, 2017
)
0.46
" The objective of the study was to determine the effect of three different PGF2α (PGF) dosage schemes on artificial insemination (AI) pregnancy rates in beef heifers."( Fertility after two doses of PGF2α concurrently or at 6-hour interval on the day of CIDR removal in 5-day CO-Synch progesterone-based synchronization protocols in beef heifers.
Kasimanickam, RK; Kasimanickam, VR; White, SS, 2016
)
0.43
"2 ml 35 µM indomethacin solution (resulting in a final concentration of 8 µg/ml in the follicular fluid) was the minimal dosage leading to COF formation."( Induction of cystic ovarian follicles (COFs) in cattle by using an intrafollicular injection of indomethacin.
Lapp, R; Röttgen, V; Vernunft, A; Viergutz, T; Weitzel, JM, 2020
)
0.56
" We observed positive dose-response relationships between all eight urinary heavy metals and 8-iso-PGF2α, as well as negative association of urinary 8-iso-PGF2α with SDNN and total power (all P trend<0."( Heavy metals exposure, lipid peroxidation and heart rate variability alteration: Association and mediation analyses in urban adults.
Chen, W; Ma, J; Mu, G; Nie, X; Tan, Q; Wang, B; Wang, D; Zhang, X; Zhou, M, 2020
)
0.56
" Multiday dosing (daily for 3 days) of latanoprost also was evaluated."( Prostaglandin analog effects on cerebrospinal fluid reabsorption via nasal mucosa.
Pedler, MG; Petrash, JM; Subramanian, PS, 2021
)
0.62
" The objective of this study was to establish if a dose-response relationship exists between Vit D exposure and success of in vitro production (IVP) of embryos and, if acute supplementation of Vit D improves pregnancy rates during timed artificial insemination (TAI) of dairy cows."( Increasing vitamin D levels to improve fertilization rates in cattle.
Bishop, CV; Estill, CT; Jensen, J; Peixoto de Souza, V; Whitler, W, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
prostaglandins Falpha
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (21)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
Signaling Pathways1269117
Signaling by GPCR24955
GPCR ligand binding19339
Class A/1 (Rhodopsin-like receptors)16136
Eicosanoid ligand-binding receptors117
Prostanoid ligand receptors75
GPCR downstream signalling17252
G alpha (q) signalling events7928
Prostaglandin and Leukotriene metabolism ( Prostaglandin and Leukotriene metabolism )2223
Eicosanoid metabolism via cyclooxygenases (COX)137
Prostaglandin and leukotriene metabolism in senescence619
Arachidonic acid (AA, ARA) oxylipin metabolism076
Eicosanoid lipid synthesis map17
Eicosanoid synthesis026
Arachidonic acid metabolism pathway011
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency1.50890.000221.22318,912.5098AID743035; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.19000.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.79820.000229.305416,493.5996AID743069; AID743075; AID743079; AID743080; AID743091
lamin isoform A-delta10Homo sapiens (human)Potency31.62280.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)0.00250.00051.41288.2000AID160700
Prostaglandin G/H synthase 2 Bos taurus (cattle)IC50 (µMol)0.07130.00050.57393.4000AID160700; AID160702
Thromboxane A2 receptor Homo sapiens (human)IC50 (µMol)5.00000.00110.71065.2000AID161214; AID210159
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)0.14000.00021.557410.0000AID160702
Prostaglandin E2 receptor EP1 subtypeHomo sapiens (human)IC50 (µMol)0.30000.00110.22540.4960AID160913; AID160915
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)0.14000.00010.995010.0000AID160702
Prostaglandin E2 receptor EP4 subtypeHomo sapiens (human)IC50 (µMol)4.20000.00040.95858.0390AID161070; AID161071
Prostaglandin F2-alpha receptorBos taurus (cattle)IC50 (µMol)0.14000.14000.14000.1400AID160702
Prostaglandin F2-alpha receptorBos taurus (cattle)Ki0.12900.12900.12900.1290AID238750
Prostaglandin F2-alpha receptorHomo sapiens (human)IC50 (µMol)0.01390.00100.01060.0430AID160700; AID160703; AID161196; AID223522
Prostaglandin F2-alpha receptorHomo sapiens (human)Ki0.11900.03103.38039.9910AID161200
Prostaglandin E2 receptor EP3 subtypeHomo sapiens (human)IC50 (µMol)0.21600.00090.12120.6350AID161055; AID161057
Prostaglandin E2 receptor EP2 subtypeHomo sapiens (human)IC50 (µMol)55.00000.00220.72054.1690AID161039; AID161041
Prostacyclin receptorHomo sapiens (human)IC50 (µMol)55.00000.00840.07040.2880AID160747; AID161205
Solute carrier organic anion transporter family member 2A1Rattus norvegicus (Norway rat)Ki0.04500.03821.41225.8000AID679943
Prostaglandin D2 receptorHomo sapiens (human)IC50 (µMol)4.50000.00011.15837.3000AID160529; AID160909
Solute carrier organic anion transporter family member 2A1Homo sapiens (human)Ki0.02300.02300.07000.1490AID679658
Solute carrier organic anion transporter family member 2A1Mus musculus (house mouse)Ki0.10400.09800.10100.1040AID679648
Solute carrier organic anion transporter family member 2B1Rattus norvegicus (Norway rat)IC50 (µMol)0.28700.03580.16140.2870AID679647
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thromboxane A2 receptor Homo sapiens (human)EC50 (µMol)1.40000.02400.98102.4000AID212941
Prostaglandin E2 receptor EP1 subtypeHomo sapiens (human)EC50 (µMol)0.60000.00030.32480.7600AID160545
Prostaglandin F2-alpha receptorHomo sapiens (human)EC50 (µMol)0.05180.00360.07620.2500AID160696; AID246471
Prostaglandin E2 receptor EP3 subtypeHomo sapiens (human)EC50 (µMol)2.30000.00252.54055.0000AID160552
Prostaglandin F2-alpha receptorMus musculus (house mouse)EC50 (µMol)0.01850.00630.01880.0317AID347678; AID726602
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)Km0.33400.02891.04072.6000AID682098
Solute carrier family 22 member 1 Homo sapiens (human)Km0.47700.47704.03089.0000AID680361
Solute carrier organic anion transporter family member 2A1Rattus norvegicus (Norway rat)Km0.10400.07001.65207.5690AID681576
Solute carrier family 22 member 6Homo sapiens (human)Km0.57500.42004.61839.3000AID679829
Solute carrier family 22 member 7Rattus norvegicus (Norway rat)Km0.41400.36600.39000.4140AID679359
Solute carrier family 22 member 8Homo sapiens (human)Km1.09200.34501.32173.1000AID679674
Solute carrier organic anion transporter family member 2A1Homo sapiens (human)K1/20.09200.08200.10780.1820AID682149
Solute carrier family 22 member 11Homo sapiens (human)Km0.69200.15400.62151.0100AID679645
Solute carrier family 22 member 7Homo sapiens (human)Km0.42500.42500.56900.7130AID679510
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (169)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
meiotic spindle organizationProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin biosynthetic processProstaglandin G/H synthase 2 Bos taurus (cattle)
ovarian cumulus expansionProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of protein phosphorylationProstaglandin G/H synthase 2 Bos taurus (cattle)
response to oxidative stressProstaglandin G/H synthase 2 Bos taurus (cattle)
cyclooxygenase pathwayProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of embryonic developmentProstaglandin G/H synthase 2 Bos taurus (cattle)
cellular response to interleukin-1Prostaglandin G/H synthase 2 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 2 Bos taurus (cattle)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of meiotic cell cycle process involved in oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to nutrientThromboxane A2 receptor Homo sapiens (human)
response to xenobiotic stimulusThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood coagulationThromboxane A2 receptor Homo sapiens (human)
response to testosteroneThromboxane A2 receptor Homo sapiens (human)
thromboxane A2 signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to ethanolThromboxane A2 receptor Homo sapiens (human)
positive regulation of angiogenesisThromboxane A2 receptor Homo sapiens (human)
positive regulation of smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
cellular response to lipopolysaccharideThromboxane A2 receptor Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisThromboxane A2 receptor Homo sapiens (human)
inflammatory responseThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood pressureThromboxane A2 receptor Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane A2 receptor Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationThromboxane A2 receptor Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
response to lipopolysaccharideProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
inflammatory responseProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cytokine productionProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
positive regulation of cytokine productionProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
immune responseProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
JNK cascadeProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
response to mechanical stimulusProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
response to nematodeProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
regulation of ossificationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
response to lipopolysaccharideProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
negative regulation of integrin activationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
T-helper cell differentiationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
negative regulation of inflammatory responseProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
positive regulation of inflammatory responseProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
regulation of stress fiber assemblyProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
bone developmentProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
ERK1 and ERK2 cascadeProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
cellular response to mechanical stimulusProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
negative regulation of eosinophil extravasationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
cellular response to prostaglandin E stimulusProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
inflammatory responseProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin F2-alpha receptorHomo sapiens (human)
parturitionProstaglandin F2-alpha receptorHomo sapiens (human)
positive regulation of cell population proliferationProstaglandin F2-alpha receptorHomo sapiens (human)
positive regulation of gene expressionProstaglandin F2-alpha receptorHomo sapiens (human)
response to estradiolProstaglandin F2-alpha receptorHomo sapiens (human)
response to lipopolysaccharideProstaglandin F2-alpha receptorHomo sapiens (human)
negative regulation of apoptotic processProstaglandin F2-alpha receptorHomo sapiens (human)
cellular response to prostaglandin D stimulusProstaglandin F2-alpha receptorHomo sapiens (human)
inflammatory responseProstaglandin F2-alpha receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin F2-alpha receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstaglandin F2-alpha receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
cell deathProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
positive regulation of fever generationProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
intestine smooth muscle contractionProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
inflammatory responseProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
negative regulation of gastric acid secretionProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
response to nematodeProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
response to lipopolysaccharideProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
response to progesteroneProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
regulation of cell population proliferationProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
cellular response to prostaglandin E stimulusProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
inflammatory responseProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerProstacyclin receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstacyclin receptorHomo sapiens (human)
cell-cell signalingProstacyclin receptorHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayProstacyclin receptorHomo sapiens (human)
response to lipopolysaccharideProstacyclin receptorHomo sapiens (human)
negative regulation of smooth muscle cell proliferationProstacyclin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstacyclin receptorHomo sapiens (human)
inflammatory responseProstacyclin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProstaglandin D2 receptorHomo sapiens (human)
male sex determinationProstaglandin D2 receptorHomo sapiens (human)
sleepProstaglandin D2 receptorHomo sapiens (human)
mast cell degranulationProstaglandin D2 receptorHomo sapiens (human)
adenosine metabolic processProstaglandin D2 receptorHomo sapiens (human)
cellular response to prostaglandin D stimulusProstaglandin D2 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstaglandin D2 receptorHomo sapiens (human)
inflammatory responseProstaglandin D2 receptorHomo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
lipid transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 11Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 11Homo sapiens (human)
organic anion transportSolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 11Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 11Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 11Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 7Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 7Homo sapiens (human)
organic anion transportSolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 7Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (46)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
peroxidase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
thromboxane A2 receptor activityThromboxane A2 receptor Homo sapiens (human)
guanyl-nucleotide exchange factor activityThromboxane A2 receptor Homo sapiens (human)
protein bindingThromboxane A2 receptor Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
D1 dopamine receptor bindingProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
prostaglandin E receptor activityProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin E receptor activityProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
protein bindingProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
prostaglandin F receptor activityProstaglandin F2-alpha receptorHomo sapiens (human)
prostaglandin E receptor activityProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
prostaglandin E receptor activityProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
guanyl-nucleotide exchange factor activityProstacyclin receptorHomo sapiens (human)
prostacyclin receptor activityProstacyclin receptorHomo sapiens (human)
prostaglandin J receptor activityProstaglandin D2 receptorHomo sapiens (human)
prostaglandin D receptor activityProstaglandin D2 receptorHomo sapiens (human)
protein bindingProstaglandin D2 receptorHomo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
lipid transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 11Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 7Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
nuclear inner membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
nuclear outer membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
endoplasmic reticulum membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
acrosomal vesicleThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
nuclear speckThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
plasma membraneProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP1 subtypeHomo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
plasma membraneProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
membraneProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP4 subtypeHomo sapiens (human)
extracellular regionProstaglandin F2-alpha receptorHomo sapiens (human)
cytoplasmProstaglandin F2-alpha receptorHomo sapiens (human)
plasma membraneProstaglandin F2-alpha receptorHomo sapiens (human)
plasma membraneProstaglandin F2-alpha receptorHomo sapiens (human)
nuclear envelopeProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
membraneProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP3 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
plasma membraneProstaglandin E2 receptor EP2 subtypeHomo sapiens (human)
cytosolProstacyclin receptorHomo sapiens (human)
plasma membraneProstacyclin receptorHomo sapiens (human)
plasma membraneProstacyclin receptorHomo sapiens (human)
plasma membraneProstaglandin D2 receptorHomo sapiens (human)
membraneProstaglandin D2 receptorHomo sapiens (human)
plasma membraneProstaglandin D2 receptorHomo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
lysosomeSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
external side of plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 11Homo sapiens (human)
cytosolSolute carrier family 22 member 7Homo sapiens (human)
plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
membraneSolute carrier family 22 member 7Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (129)

Assay IDTitleYearJournalArticle
AID1346372Mouse EP1 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346425Mouse FP receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346345Rat EP1 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346408Human EP1 receptor (Prostanoid receptors)2002The Journal of pharmacy and pharmacology, Apr, Volume: 54, Issue:4
Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques.
AID1346318Rat EP2 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346343Human EP3 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346308Human EP2 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346427Human EP4 receptor (Prostanoid receptors)2009The Journal of pharmacology and experimental therapeutics, Oct, Volume: 331, Issue:1
Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands.
AID1346326Human DP2 receptor (Prostanoid receptors)2002British journal of pharmacology, Dec, Volume: 137, Issue:8
Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
AID1346394Human FP receptor (Prostanoid receptors)2006British journal of pharmacology, Jun, Volume: 148, Issue:3
GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.
AID1346422Human TP receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346427Human EP4 receptor (Prostanoid receptors)2000British journal of pharmacology, Aug, Volume: 130, Issue:8
Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.
AID1346408Human EP1 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346396Rat EP3 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346353Rat EP4 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346336Mouse EP3 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346427Human EP4 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346394Human FP receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346308Human EP2 receptor (Prostanoid receptors)1999Molecular pharmacology, Sep, Volume: 56, Issue:3
Importance of the extracellular domain for prostaglandin EP(2) receptor function.
AID1346401Mouse DP2 receptor (Prostanoid receptors)2003The Journal of pharmacology and experimental therapeutics, Aug, Volume: 306, Issue:2
Expression and molecular pharmacology of the mouse CRTH2 receptor.
AID1346377Human DP1 receptor (Prostanoid receptors)1998British journal of pharmacology, Apr, Volume: 123, Issue:7
Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
AID1346377Human DP1 receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
AID1346427Human EP4 receptor (Prostanoid receptors)1999Molecular pharmacology, Sep, Volume: 56, Issue:3
Importance of the extracellular domain for prostaglandin EP(2) receptor function.
AID1346394Human FP receptor (Prostanoid receptors)2003The Biochemical journal, Apr-15, Volume: 371, Issue:Pt 2
Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor.
AID347687Effect on ocular irritation in New Zealand albino rabbit assessed as incidence of conjunctival hyperemia at 1 ug after 1 to 5 hrs2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID1132558Interruption of pregnancy in hamster at 12.5 ug, sc administered on day 3 of pregnancy relative to control1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Synthesis and biological evaluation of 10-oxa-11-deoxyprostaglandin E1 and 10-nor-9,11-secoprostaglandin F1 and their derivatives.
AID160913Affinity for Prostanoid EP1 receptor expressed in COS-7 cells.2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
AID160702Binding potency towards Prostaglandin F2 alpha receptor (competitive binding) with natural [3H]-PGF 2 alpha in bovine corpora lutea plasma membranes (BCLM)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Prostaglandin photoaffinity probes: synthesis and biological activity of azide-substituted 16-phenoxy- and 17-phenyl-PGF2 alpha prostaglandins.
AID681871TP_TRANSPORTER: inhibition of alaninyl-d4TMP by Prostaglandin F2alpha at a concentration of 20uM in membrane vesicle from MRP5-expressing HEK293 cells2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID196887in vivo urinary excretion of PGF2-alpha metabolite in rats, when administered sc (1 mg/rat) urinary excretion on day 11983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID127108Plasma hydrolysis following 20 hr incubation with monkey plasma1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID85831Compound was evaluated for antifertility activity relative to PGF2-alpha in hamsters1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis and biological evaluation of the methyl esters of (+)-12-fluoro-13,14-dihydroprostaglandin F2alpha and (+)-15-epi-12-fluoro-13,14-dihydroprostaglandin F2alpha.
AID193785Plasma hydrolysis following 20 hr incubation with rat plasma1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID680361TP_TRANSPORTER: uptake in OCT1-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID161057In vitro binding at EP3 human prostaglandin receptor using [3H]PGE-2 as radioligand2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
AID347679Agonist activity at FP receptor in Swiss mouse 3T3 cells assessed as [3H]-IP accumulation by scintillation counting relative to control2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID1131076Hypotensive activity in iv dosed PGE2-treated Mongrel dog assessed as change in blood pressure of greater than 10 mm by mercury manometer relative to PGE21979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues.
AID182632Compound was evaluated for antisecretion activity using stomach perfusion test in the anesthetized rat (iv administration); At the dose of 500 ug/kg, some animals died1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Structure-activity studies of 16-methoxy-16-methyl prostaglandins.
AID86003Compound was evaluated for uterine contraction relative to PGF2-alpha in hamsters1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis and biological evaluation of the methyl esters of (+)-12-fluoro-13,14-dihydroprostaglandin F2alpha and (+)-15-epi-12-fluoro-13,14-dihydroprostaglandin F2alpha.
AID126987Plasma hydrolysis following 2 hr incubation with monkey plasma1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID223522In vitro binding at FP human prostaglandin receptor using [3H]PGF-2 alpha as radioligand2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
AID251222Percent response for stimulation of prostanoid FP receptor-linked phosphoinositide turnover in Swiss 3T3 mouse fibroblast cells2004Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey.
AID160909In vitro binding at DP human prostaglandin receptor using [3H]- PGD-2 as radioligand2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID681975TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, PGF2alpha: 1000 uM) in OCT2-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID347677Displacement of [3H]PGF2 alpha from FP receptor in bovine corpus luteum membrane2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID161214Affinity for Prostanoid TP receptor expressed in CHO cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
AID726602Agonist activity at FP receptor in mouse 3T3 fibroblast cells assessed as intracellular calcium mobilization by FLIPR2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
AID1133294Antisecretory activity in rat assessed as decrease in total acid at 1.5 mg/kg, sc immediately after surgery and again 2 hrs later measured after 4 hrs of pyloric ligation1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and gastric antisecretory properties of an 8-aza-and a 10-oxa-8,12-secoprostaglandin.
AID1133293Antisecretory activity in rat assessed as decrease in volume of gastric secretion at 1.5 mg/kg, sc immediately after surgery and again 2 hrs later measured after 4 hrs of pyloric ligation1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and gastric antisecretory properties of an 8-aza-and a 10-oxa-8,12-secoprostaglandin.
AID90848Plasma hydrolysis following 2 h incubation with hog liver esterase1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID726601Intrinsic activity at FP receptor in mouse 3T3 fibroblast cells assessed as maximum compound-evoked response2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
AID91232Plasma hydrolysis following 2 hr incubation with human plasma1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID25586Dissociation constant was determined2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
AID679510TP_TRANSPORTER: uptake in OAT2-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID681576TP_TRANSPORTER: uptake in PGT-expressing HeLa cells1995Science (New York, N.Y.), May-12, Volume: 268, Issue:5212
Identification and characterization of a prostaglandin transporter.
AID679359TP_TRANSPORTER: uptake in OAT2-S2 cells2003European journal of pharmacology, Mar-28, Volume: 465, Issue:1-2
Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.
AID238750Binding affinity for Prostanoid FP receptor of bovine corpus luteum2004Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey.
AID160545Functional activity in RAT-1cells, transiently-transfected with human Prostaglandin E receptor EP1 (% of control ligand, 17-phi-PGE2=80%)2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues.
AID161205In vitro binding at prostanoid IP receptor using [3H]iloprost as radioligand2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID193784Plasma hydrolysis following 2 hr incubation with rat plasma1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID680178TP_TRANSPORTER: inhibition of ES uptake (ES: 0.05 uM, PGF2alpha: 30 uM) in OAT4-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID160700Displacement of [3H]PGF2-alpha from human FP-receptor expressed in CHO-KI cells2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues.
AID246471Efficacy for stimulation of prostanoid FP receptor-linked phosphoinositide turnover in Swiss 3T3 mouse fibroblast cells2004Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey.
AID91063Plasma hydrolysis following 20 hr incubation with human plasma1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID679645TP_TRANSPORTER: uptake in OAT4-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID680248TP_TRANSPORTER: transport activity2000Seminars in liver disease, , Volume: 20, Issue:3
Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver.
AID347678Agonist activity at FP receptor in Swiss mouse 3T3 cells assessed as [3H]-IP accumulation by scintillation counting2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID160529Affinity for human Prostaglandin D2 receptor expressed in HEK293 cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
AID160552Functional activity in RAT-1cells, transiently-transfected with human Prostaglandin E receptor EP3 (% of control ligand, sulprostone=50%)2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues.
AID160747Affinity for Prostaglandin I2 receptor expressed in CHO cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
AID679674TP_TRANSPORTER: uptake in OAT3-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID681367TP_TRANSPORTER: uptake in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
AID196888in vivo urinary excretion of PGF2-alpha metabolite in rats, when administered sc (1 mg/rat) urinary excretion on day 21983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID679658TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells1999The American journal of physiology, 09, Volume: 277, Issue:3
Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities.
AID679943TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells1999The American journal of physiology, 09, Volume: 277, Issue:3
Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID726600Permeability across human Caco2 cells2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
AID161041In vitro binding at EP2 human prostaglandin receptor using [3H]PGE-2 as radioligand2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID160696Functional activity in RAT-1cells, transiently-transfected with human FP-receptor (% of control ligand, fluprostenol=75%)2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues.
AID679647TP_TRANSPORTER: inhibition of PGD2 uptake in Xenopus laevis oocytes2000Biochemical and biophysical research communications, Sep-07, Volume: 275, Issue:3
Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.
AID209329Evaluated for its concentration at which 50% of maximal stimulation of phosphoinositide turnover was observed2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Synthesis and biological activity of a novel 11a-homo (cyclohexyl) prostaglandin.
AID129964Compound was evaluated for diarrheal effect in mice (po administration)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Structure-activity studies of 16-methoxy-16-methyl prostaglandins.
AID47784Concentration giving half-maximal contraction of the cat iris sphincter muscle was determined in vitro1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Derivatives of 17-phenyl-18,19,20-trinorprostaglandin F2 alpha isopropyl ester: potential antiglaucoma agents.
AID682149TP_TRANSPORTER: uptake in PGT-expressing HeLa cells1996The Journal of clinical investigation, Sep-01, Volume: 98, Issue:5
Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT).
AID161200Inhibitory Binding constant (n=2) to Prostanoid FP receptor expressed in bovine corpus luteum2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Synthesis and biological activity of a novel 11a-homo (cyclohexyl) prostaglandin.
AID209332Evaluated for percent maximum response relative to cloprostenol (n=11)2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Synthesis and biological activity of a novel 11a-homo (cyclohexyl) prostaglandin.
AID679829TP_TRANSPORTER: uptake in OAT1-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID681939TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, PGF2alpha: 1000 uM) in OCT1-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID75111Compound was evaluated for gerbil colon contraction relative to PGF2-alpha1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis and biological evaluation of the methyl esters of (+)-12-fluoro-13,14-dihydroprostaglandin F2alpha and (+)-15-epi-12-fluoro-13,14-dihydroprostaglandin F2alpha.
AID161039Affinity for Prostanoid EP2 receptor expressed in CHO cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
AID84686Antifertility activity was determined in hamsters (two to six dose levels, 6-18 animals per group) treated subcutaneously (sc) from day 4 to day 6 of gestation.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Structure-activity studies of 16-methoxy-16-methyl prostaglandins.
AID161055Affinity for Prostanoid EP3 receptor expressed in CHO cell line2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
AID681386TP_TRANSPORTER: uptake in mOat3-expressing oocytes2004Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 32, Issue:5
Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.
AID1132632Abortifacient activity in sc dosed early pregnant Wistar rat assessed as decrease in serum progesterone level measured per animal administered in benzyl benzoate and castor oil on day 4 to day 7 of gestation measured on day 3, 5, 7 and 9 of gestation by R1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
15,15-Ketals of natural prostaglandins and prostaglandin analogues. Synthesis and biological activities.
AID161196Affinity for human Prostanoid FP receptor expressed in COS-7 cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
AID90849Plasma hydrolysis following 20 hr incubation with hog liver esterase1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID210159In vitro binding at TP human prostaglandin receptor using [3H]SQ-29,548 as radioligand2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
AID679648TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells1999The American journal of physiology, 09, Volume: 277, Issue:3
Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities.
AID682098TP_TRANSPORTER: uptake in OCT2-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID682160TP_TRANSPORTER: inhibition of alaninyl-d4TMP in the presence of Prostaglandin F2alpha at a concentration of 20uM in membrane vesicles from MRP4-expressing Sf9 cells2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID679297TP_TRANSPORTER: uptake in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
AID347688Effect on ocular irritation in New Zealand albino rabbit assessed as incidence of conjunctival swelling at 1 ug after 1 to 5 hrs2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID1131074Spasmogenic activity in nulliparous guinea pig uterine relative to PGE21979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues.
AID726599Corneal permeability in rabbit corneal tissues mounted on vertical Using chambers2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
AID679402TP_TRANSPORTER: inhibition of PAH uptake (PAH: 5 uM, PGF2alpha: 1000 uM) in OAT1-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID682138TP_TRANSPORTER: inhibition of PGE2 uptake (PGE2: 0.015 uM) by Prostaglandin F2alpha at 0.15uM in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
AID212941Functional activity in RAT-1cells, transiently-transfected with human TP-receptor (% of control ligand, [3H]-U-46,619=95%)2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues.
AID681173TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000Biochemical and biophysical research communications, Sep-07, Volume: 275, Issue:3
Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.
AID22264Plasma hydrolysis of percent cross reaction of substrate with PGF2-alpha antisera1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Synthesis and biological activity of prostaglandin lactones.
AID681041TP_TRANSPORTER: inhibition of ES uptake (ES: 0.05 uM, PGF2alpha: 30 uM) in OAT3-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Apr, Volume: 301, Issue:1
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.
AID161070Affinity for Prostanoid EP4 receptor expressed in CHO cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.
AID1131079Induction of diarrheal activity in conscious mouse at 0.1 to 3 mg/kg, iv administered for 30 mins relative to PGE21979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues.
AID161071In vitro binding at EP4 human prostaglandin receptor using [3H]PGE-2 as radioligand2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID160703Binding potency towards Prostaglandin F2 alpha receptor (competitive binding) with natural [3H]-PGF 2 alpha in ovine luteal cells (OLC)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Prostaglandin photoaffinity probes: synthesis and biological activity of azide-substituted 16-phenoxy- and 17-phenyl-PGF2 alpha prostaglandins.
AID160915In vitro binding at EP1 human prostaglandin receptor using [3H]PGE-2 as radioligand2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.
AID347689Effect on ocular irritation in New Zealand albino rabbit assessed as incidence of ocular discharge at 1 ug after 1 to 5 hrs2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11,142)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903217 (28.87)18.7374
1990's3004 (26.96)18.2507
2000's2740 (24.59)29.6817
2010's1840 (16.51)24.3611
2020's341 (3.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.19 (24.57)
Research Supply Index9.43 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index112.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials940 (8.14%)5.53%
Reviews422 (3.65%)6.00%
Case Studies107 (0.93%)4.05%
Observational19 (0.16%)0.25%
Other10,066 (87.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT01379560]Phase 233 participants (Actual)Interventional2011-05-31Completed
Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of Prostaglandin F2alpha [NCT01327118]12 participants (Anticipated)Interventional2010-09-30Completed
In Vitro Myometrial Contractions in Laboring and Non-laboring Women: Oxytocin is Superior to Other Uterotonic Agents [NCT01689311]53 participants (Actual)Interventional2009-03-31Completed
A Proof-Of-Concept Phase 1b/2a Randomized, Vehicle, and Comparator-Controlled Study of Topical DLQ01 to Assess the Safety and Efficacy in the Treatment of Androgenetic Alopecia (AGA) in Men [NCT05636904]Phase 1/Phase 2120 participants (Actual)Interventional2022-12-05Active, not recruiting
Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial [NCT03584854]Phase 4100 participants (Actual)Interventional2019-03-01Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]